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Abstract
lnterleukin-6 (IL-6) is a pro-inflammatory cytokine produced by macrophages, 
endothelial cells, fibroblasts, vascular smooth muscle cells, T lymphocytes 
and adipocytes. IL-6 is regulated at the level of transcription. There are 
multiple regulatory elements in the IL-6 promoter. Three single nucleotide 
polymorphisms at position -597, -572 and -174 and a variable region of A’s 
and T’s at -373 have been identified in the IL-6 proximal promoter.
The THP-1 macrophage-like cell line was induced to express IL-6 mRNA in 
response to IFN-y and LPS. Interferon-gamma induced IL-6 mRNA 
expression was inhibited by treatment with either atorvastatin or pravastatin. 
Monocytes extracted from the blood of healthy volunteers of known IL-6 
promoter haplotype (+GG9/11G and -GG9/11G) were differentiated to 
macrophages ex vivo. These cells were cultured in the presence of IL-1p, 
LPS or IFN-y, to induce IL-6 mRNA. Quantitative PCR was used to 
quantitate the level of IL-6 mRNA. IL-6 mRNA in macrophages from 
individuals with the IL-6 promoter haplotype +GG9/11G was significantly 
induced in response to IL-1p when compared to -GG9/11G individuals. A 
similar though non significant effect was detected in response to IFN-y. No 
significant IL-6 promoter haplotype-specific difference was observed in 
response to LPS.
Chromatin remodeling of the IL-6 promoter occurred within 30 minutes of 
stimulation and was specific to the region of the IL-6 promoter and the 
stimulus applied to the cells. A DNase I hypersensitive site was identified in
11
the region of the polymorphic AnTn variable tract and a potential DNA 
cruciform structure in the IL-6 promoter was resolved by T7 Endonuclease I. 
Atomic force microscopy was used to visualise DNA cruciform structure in IL- 
6 promoter haplotype constructs.
This work contributes to the understanding of the molecular mechanisms 
underlying the normal inter-individual differences in the macrophage IL-6 
inflammatory response.
Ill
Table of contents
Abstract ii
Table of contents iv
Tables and Figures viii
Acknowledgements xi
Abbreviations xli
Chapter 1 Introduction 1
1.1 Overview 1
1.2 Actions of lnterleukin-6 1
1.3 lnterleukin-6 receptor 2
1.4 lnterleukin-6 gene 3
1.5 lnterleukin-6 promoter 3
1.6 lnterleukin-6 promoter polymorphisms 5
1.7 Polymorphisms and disease 6
1.8 lnterleukin-6 promoter polymorphisms and disease 7
1.8.1 lnterleukin-6 and cardiovascular disease 7
1.8.2 lnterleukin-6 and rheumatoid arthritis 14
1.8.3 lnterleukin-6 and obesity 16
1.8.4 lnterleukin-6 and type 2 diabetes mellitus 17
1.8.5 lnterleukin-6 and inflammatory bowel disease 18
1.8.6 lnterleukin-6 and aging 19
1.8.7 lnterleukin-6 and other studies 20
1.8.8 lnterleukin-6 and population studies 23
1.8.9 Studies showing no association with IL-6 promoter polymorphisms 24
1.9 Hypothesis 27
1.9.1 Objectives 27
Chapter 2 Materials and Methods 28
2.1 Suppliers 28
2.2 Ethics 28
2.3 Recruitment of volunteers 28
2.4 Experimental design 29
2.5 Genomic DNA extraction 29
2.6 Genotyping for IL-6 promoter polymorphisms 30
2.6.1 Restriction fragment length polymorphism (RFLP) 32
2.6.2 Fragment analysis 32
2.6.3 PyroSequencing 33
2.7 THP-1 cell line culture 38
2.7.1 Differentiation of THP-1 cells 38
2.7.2 Stimulation of THP-1 cells 38
IV
2.7.3 Statin treatment 39
2.8 Extraction of RNA 39
2.9 Quantitative PCR (QPGR) 40
2.9.1 Primer design 40
2.9.2 QPGR method 41
2.10 Measurement of IL-6 in tissue culture supernatants and plasma 41
2.10.1 IL-6 high sensitivity ELISA 42
2.11 Primary monocyte-derived macrophage culture 42
2.11.1 Isolation of mononuclear cells from whole blood 42
2.11.2 Ex vivo primary cell culture 43
2.12 Chromatin accessibility real time PGR (GHART-PGR) 43
2.12.1 Nuclei extraction 44
2.12.2 DNase I digestion 45
2.12.3 Preparation of genomic DNA from nuclei 45
2.12.4 GHART-PGR assay design 46
2.13. T7 Endonuclease I digestion 46
2.14 Atomic Force Microscopy 50
2.14.1 Sample preparation 50
2.14.2 Scanning conditions 50
2.15 Statistical analysis 51
Chapter 3 IL-6 gene expression in THP-1 cell line 52
3.1 THP-1 cells 52
3.1.1 Haplotype determination of THP-1 cells 52
3.1.2 Measuring IL-6 mRNA expression in THP-1 cells 53
3.2 IL-6 mRNA expression in THP-1 cells 59
3.2.1 Induction of IL-6 mRNA expression in macrophage-like THP-1 cells treated for 24 
hours 59
3.2.2 Induction of IL-6 mRNA expression in monocytic and macrophage-like THP-1 cells 
treated for 24 hours 60
3.2.3 Dose response of THP-1 cells to Interferon-y 61
3.3 Inhibition of IL-6 mRNA expression in THP-1 cells 62
3.3.1 Effect of statins on endogenous IL-6 mRNA expression 62
3.3.2 Effect of statins on IL-6 mRNA expression in macrophage-like THP-1 cells stimulated 
with IFN-y 62
3.4 IL-6 gene expression in THP-1 cells 64
3.4.1 IL-6 mRNA expression in THP-1 cells stimulated for 16 hours 64
3.4.2 Measuring IL-6 protein concentration in cell culture supernatants 64
3.4.3 IL-6 protein expression in THP-1 cells stimulated for 16 hours 66
3.5. Gonclusions 67
Chapter 4 IL-6 expression in primary monocyte-derived macrophages 68
4.1 Ex vivo culture of monocyte-derived macrophages 68
4.2 IL-6 mRNA expression in primary monocyte-derived macrophages 70
4.2.1 IL6 expression in unstimulated differentiating monocyte-derived macrophages 72
4.2.2 Inter-individual IL-6 mRNA expression in unstimulated primary monocyte-derived 
macrophages 74
4.3 IL-6 mRNA expression in stimulated primary monocyte-derived macrophages 77
4.3.1 Intra-individual IL-6 mRNA expression in stimulated primary monocyte-derived 
macrophages 77
4.3.2 IL-6 mRNA expression in stimulated primary monocyte-derived macrophages 79
4.3.3 IL-6 mRNA expression in stimulated monocyte-derived macrophages by haplotype80
4.4 IL-6 protein expression in human plasma and primary cell culture supernatants 84
4.4.1 IL-6 protein in human plasma 84
4.4.2 IL-6 protein concentration in ex vivo cell culture supernatants 86
4.5 Conclusions 91
Chapter 5 Chromatin remodelling In the IL-6 promoter 93
5. 1 IL-6 promoter chromatin accessibility in THP-1 cells 93
5.1.1 Design of GHART-PGR assay 93
5.1.2 Optimisation of GHART-PGR assay 94
5.1.3 Chromatin accessibility in IL-6 promoter in THP-1 cells 97
5.2 Chromatin accessibility in IL-6 promoter in primary monocyte-derived macrophages 100
5.2.1 Chromatin remodelling in the IL-6 promoter at 2 and 8 hours of stimulation 100
5.2.2 Haplotype-specific IL-6 promoter chromatin accessibility 105
5.2.2 Chromatin remodelling in the IL-6 promoter over a short time- course of IL-1(3
stimulation 107
5.3 DNase I hypersensitivity in the IL-6 promoter 110
5.4 Gonclusions 112
Chapter 6 Secondary structure In the IL-6 promoter 114
6.1 Cruciform structure in the IL-6 promoter 114
6.1.1 Validating the T7 Endonuclease I assay 114
6.1.2 Cruciform structure in IL-6 promoter haplotype constructs 116
6.2 Cruciform structure in the IL-6 promoter in functional nuclei from primary monocyte- 
derived macrophages 119
6.3 DNA structure and folding predictions 122
6.4 Atomic force microscopy of DNA cruciform structure 126
6.4.1 Cruciform structure in pUG(AT9) 126
6.4.2 Cruciform structure in IL-6 promoter haplotype constructs 133
6.5 Gonclusions 136
VI
Chapter 7 Discussion 138
7.1 THP-1 cell line ; a monocyte-macrophage model of the IL-6 inflammatory response 138
7.2 IL-6 gene expression in primary monocyte-derived macrophages from healthy individuals
of known IL-6 promoter haplotype 143
7.3 Mechanisms of normal IL-6 promoter activation 147
7.4 Future work 153
Appendix I Annotated lnterleukin-6 gene and promoter 157
Appendix II Detailed IL-6 promoter haplotype folding predictions 161
Appendix III lnterleukln-6 genotyping results 163
Appendix IV Poster abstracts and conference proceedings 164
Reference list 165
V ll
Tables and Figures
Figure 1.1. lnterleukin-6 and its downstream actions and targets............................................. 2
Figure 1.2. Structure of the IL-6 promoter.....................................................................................5
Table 1.1. Common haplotypes of IL-6 proximal promoter polymorphisms..............................6
Table 1.2. Summary of studies of IL-6 in atherosclerosis.......................................................... 13
Table 2.1. Methods for genotyping IL-6 polymorphisms............................................................ 31
Table 2.2. PCR-RFLP assays for genotyping IL-6 promoter polymorphisms..........................35
Table 2.3. PCR primers used for genotyping IL-6 promoter polymorphisms...........................36
Table 2.4. Primers used for PSQ genotyping of IL-6 promoter -1586 and -1363 and IL-6
intron 2 and intron 3.........................................................................................................................37
Table 2.5. Inflammatory stimuli used for inducing IL-6 in THP-1 cells.....................................39
Figure 2.1. Summary of CHART-PCR assay............................................................................. 44
Figure 2.2. Annotated IL-6 promoter sequence..........................................................................47
Figure 2.3. IL-6 proximal promoter showing CHART-PCR regions....................................... ..48
Table 2.6. PCR primers used for IL-6 promoter CHART-PCR.................................................. 49
Figure 3.1. Phase contrast light microscopy of THP-1 ce lls .....................................................54
Figure 3.2. Standard curves for IL-6 and MLN51 mRNA expression........................................55
Figure 3.3. Amplification plot in duplicate samples, showing cycle threshold..........................56
Figure 3.4. Dissociation plot of IL-6 mRNA in duplicate samples............................................. 57
Figure 3.5. Amplification plots of serial dilutions of RNA............................................................ 58
Table 3.1 Induction of IL-6 mRNA expression in macrophage-iike THP-1 cells treated for 24
hours................................................................................................................................................. 59
Figure 3.6. Induction of IL-6 mRNA expression in monocytic and macrophage-iike THP-1
cells treated for 24 hours................................................................................................................60
Figure 3.7. Fold change in IL-6 mRNA expression in macrophage-like THP-1 cells treated
for 2 and 24 hours with lOOU/ml and 1000U/ml IFN-y............................................................... 61
Figure 3.8. Fold change in IL-6 mRNA expression in unstimulated macrophage-iike THP-1
cells treated with an increasing dose of statin............................................................................. 63
Figure 3.9. IL-6 mRNA expression in IFN-y stimulated macrophage-like THP-1 cells treated
with an increasing dose of statin ...................................................................................................63
Figure 3.10. IL-6 mRNA expression in monocytic and macrophage-like cells stimulated for 16
hours................................................................................................................................................. 65
Figure 3.11. Composite standard curve of IL-6 protein concentration......................................65
Figure 3.12. IL-6 protein expression in THP-1 cells stimulated for 16 hours..........................66
Table 4.1 Haplotype assignment for volunteers recruited to the study.................................... 68
Figure 4.1. Chitotriosidase mRNA expression in monocyte-derived macrophages................71
Figure 4.2. Baseline IL-6 and MLN51 mRNA expression in differentiating monocyte-derived 
macrophages................................................................................................................................... 73
Vlll
Table 4.2. Baseline IL-6 and MLN51 mRNA expression in differentiating monocyte-derived
macrophages................................................................................................................................... 73
Figure 4.3. IL-6 mRNA expression in unstimulated monocyte-derived macrophages over time
...........................................................................................................................................................75
Figure 4.4. Effect of sex on baseline IL-6 mRNA expression in monocyte-derived
macrophages................................................................................................................................... 76
Figure 4.5. Effect of age on baseline IL-6 mRNA expression in monocyte-derived
macrophages................................................................................................................................... 76
Figure 4.6. Intra-individual fold change in IL-6 mRNA expression in stimulated monocyte-
derived macrophages..................................................................................................................... 78
Figure 4.7. IL-6 and MLN51 mRNA expression in IL-1p stimulated primary monocyte-derived
macrophages................................................................................................................................... 78
Figure 4.8. induction of IL-6 mRNA expression in stimulated monocyte-derived macrophages
...........................................................................................................................................................79
Figure 4.9. IL-6 mRNA expression in IFN-y primed monocyte-derived macrophages...........80
Figure 4.10. IL-6 mRNA expression in IL-1{3 stimulated monocyte-derived macrophages by
haplotype..........................................................................................................................................82
Figure 4.11. IL-6 mRNA expression in IFN-y stimulated monocyte-derived macrophages by
haplotype..........................................................................................................................................83
Figure 4.12. IL-6 mRNA expression in LPS stimulated monocyte-derived macrophages by
haplotype..........................................................................................................................................83
Figure 4.13. Plasma IL-6 protein expression...............................................................................85
Figure 4.14. IL-6 protein concentration in cell culture supernatants from unstimulated
monocyte-derived macrophages...................................................................................................86
Figure 4.15. IL-6 protein expression in ex vivo primary cell culture supernatants from
stimulated monocyte-derived macrophages................................................................................87
Figure 4.16. IL-6 protein concentration in supernatants from primary monocyte-derived
macrophages................................................................................................................................... 88
Figure 4.17. IL-6 protein concentration in supernatants from monocyte-derived macrophages
stimulated with IL -Ip  over a short time-course........................................................................... 91
Figure 5.1. Agarose gel electrophoresis of PCR products of DNase l-digested nuclei 94
Figure 5.2. Time-course of DNase I treatment of nuclei from THP-1 ce lls ..............................95
Figure 5.3. IL-6 promoter region 1 chromatin accessibility at baseline in THP-1 ce lls ...........97
Figure 5.4. Chromatin accessibility in IL-6 promoter in THP-1 ce lls .........................................98
Figure 5.5. Chromatin accessibility in the IL-6 promoter in THP-1 ce lls ............................... 100
Figure 5.6. Chromatin accessibility in IL-6 promoter in nuclei from monocyte-derived
macrophages stimulated for 2 and 8 hours................................................................................102
Figure 5.7. Fold change in chromatin accessibility in the IL-6 promoter at 8 hours of
stimulation......................................................................................................................................104
Figure 5.8, Haplotype-specific chromatin accessibility in IL-6 promoter................................ 105
IX
Figure 5.9. Chromatin accessibility in IL-6 promoter regions over a short time-course 108
Figure 5.10. Chromatin remodelling in the IL-6 promoter........................................................ 109
Figure 5.11. Quantitative PCR product from IL-6 promoter regions.......................................110
Figure 6.1. Agarose gel electrophoresis of pUC(ATg) digested with T7 Endonuclease I .... 115
Figure 6.2 . Percentage digestion of pUC(ATs) with T7 Endonuclease 1............................... 116
Figure 6.3. Supercoiled plasmid DNA containing construct of IL-6 promoter haplotype
AG8/12C and GG9/11G ...............................................................................................................117
Figure 6.4. T7 Endonuclease I digestion of pGL3 plasmid DNA with IL-6 promoter construct
AG8/12C......................................................................................................................................... 117
Figure 6.5. Quantitative PCR of IL-6 promoter construct AG8/12C following T7
Endonuclease 1.............................................................................................................................. 118
Table 6.1. Percentage template remaining following T7 Endonuclease I digestion in region 1
and region 2 of IL-6 promoter...................................................................................................... 119
Figure 6.6. T7 Endonuclease I digestion of IL-6 promoter in nuclei from primary monocyte-
derived macrophages..................................   120
Figure 6.7. T7 Endonuclease I digestion of IL-6 promoter and IL-6 intron 3 in nuclei from
monocyte-derived macrophages  ..........................................................................................121
Table 6.2. Gibbs free energy (AG) for the most energetically favourable folding predictions of
IL-6 promoter haplotype from MFOLD....................................................................................... 123
Figure 6.8. Folding profiles of IL-6 promoter haplotype sequence.......................................... 124
Figure 6.9. Cruciform structure in supercoiled DNA..................................................................126
Figure 6.10. Atomic force microscopy images of undigested pUC(ATg)................................ 127
Figure 6.11. High resolution atomic force microscopy images of undigested pUCCATg) 129
Figure 6.12. Atomic force microscopy images of T7 Endonuclease I digested pUCCATg)... 130 
Figure 6.13. High resolution atomic force microscopy images of T7 Endonuclease I digested
pUC(ATg)........................................................................................................................................132
Figure 6.14. Atomic force microscopy images of IL-6 promoter haplotype construct
GG9/11G........................................................................................................................................134
Figure 6.15. Atomic force microscopy images of IL-6 promoter haplotype construct AG8/12C
......................................................................................................................................................... 135
Figure 7.1. A model of IL-6 promoter structure and function...................................................152
Acknowledgements
I am grateful to my supervisors Fiona Green, Kikki Bodman-Smith and 
Gordon Ferns, for the opportunity to achieve this personal goal.
Scott Ellis, formerly of the Wellcome Trust Centre for Fluman Genetics, 
Oxford, genotyped the IL-6 -373 AnTn polymorphism. Danya Agha-Jaffar, 
Visiting Researcher, carried out the IL-6 ELISA experiments under my 
supervision. Peter Tomlin, MSc project student, performed the TFIP-1 statin 
experiments under my guidance. Atorvastatin was supplied by Graham 
Smith at AstraZeneca.
Special thanks go to Elisabetta Canetta and Joe Keddie in the Department of 
Physics for their assistance and encouragement with the AFM work.
Marion Chadd tested the cell lines for mycoplasma.
Thanks to the Faculty staff for attending my seminars and contributing to 
useful discussions.
This work was funded in 2004-2005 by a Royal Surrey County Hospital 
Collaborative Grant. I was supported throughout by a University Research 
Committee Scholarship.
And last but by no means least, thanks to everyone in 19AY02 for laughs 
along the way.
X I
Abbreviations
AFM
ARE
C/EBP
CHART-PCR
CRP
ct
dTHP-1
f
FBS
RFLP
GRE
hsp
IFN-y
lL-1ra
IL-1(3
IL-6r
LPS
ng
OR
PBS
PMA
PSQ
QPCR
RFLP
slL-6r
SNP
THP-1
UTR
Atomic force microscopy
AU rich elements
CCAAT/enhancer-binding protein
Chromatin Accessibility Real Time PCR
C-reactive protein
Cycle threshold
Macrophage-like THP-1 cells
Frequency
Foetal bovine serum
Restriction fragment length polymorphism
Glucocorticoid response element
Heat shock protein
Interferon-gamma
Interleukin-1 receptor antagonist
Interleukin-1 beta
lnterleukin-6 receptor
Lipopolysaccharide
nanogram
Odds ratio
Phosphate buffered saline 
Phorbol myristate acetate 
PyroSequencing 
Quantitative PCR
Restriction fragment length polymorphism 
Soluble lnterleukin-6 receptor 
Single nucleotide polymorphism 
Monocytic THP-1 cells 
Untranslated region
Xll
Chapter 1 introduction
1.1 Overview
lnterleukin-6 (IL-6) is a 26kDa inflammatory cytokine with biological actions in 
inflammation and the regulation of endocrine and metabolic functions. IL-6 is 
produced by immune and non-immune cells, including endothelial cells, 
fibroblasts, monocytes, macrophages and T lymphocytes (Figure 1.1). IL-6 is 
a member of a larger family of cytokines including interleukin-11, oncostatin- 
M, leukemia inhibitory factor, ciliary neurotrophic factor, cardiotropin-1 and 
leptin (Papanicolaou etal, 1998; Papanicolaou and Vgontzas, 2000).
1.2 Actions o f Interieukin-6
IL-6 stimulates the hypothalamic-pituitary-adrenal axis and is suppressed by 
glucocorticoids (Ray et al, 1990; Papanicolaou et al, 1996). IL-6 stimulates 
the release of growth hormone, inhibits thyroid-stimulating hormone and 
decreases serum lipid concentrations. When the body is under stress IL-6 is 
secreted and positively controlled by catecholamines, as seen for example 
during exercise (Papanicolaou et al, 1996). Animal studies have shown that 
the administration of IL-6 leads to fever, anorexia and fatigue. Circulating 
levels of IL-6 are increased in rheumatoid arthritis and osteoporosis. IL-6 
increases body temperature and metabolic rate and is stimulated by insulin. 
C-reactive protein (CRP), an acute phase protein, is induced by IL-6, and is 
produced in the liver (Papanicolaou et al, 1998). More recently, IL-6 has 
been shown to inhibit the development of regulatory T lymphocytes, which 
provide protection against autoimmunity (Bettelli et al, 2006) and could 
implicate IL-6 in the development of autoimmune conditions, such as
rheumatoid arthritis, type 1 diabetes mellitus and inflammatory bowel 
disease.
Macrophage B cell T  cell F ibroblast M onocyte Endothelial cell
I #
Haem atopoietic B cell T  cell Hepatocytes
stem cell
i i i i
Blast cell form ation Ig production D ifferentiation Acute phase proteins
Figure 1.1. lnterleukin-6 and its downstream actions and targets
The figure shows the cells which produce IL-6 and the contribution IL-6 
makes to downstream targets (adapted from Naka etal, 2002).
1.3 lnterleukin-6 receptor
There are two forms of the interleukin-6 receptor (IL-6r); a trans-membrane 
receptor and a soluble form (slL-6r) (Peters et al, 1998; Kerr et al, 2001). 
The slL-6r is formed from the extracellular domain of the membrane-bound 
receptor, either as a result of proteolytic cleavage or by alternative mRNA 
splicing. Activation of either receptor by IL-6 induces homodimerisation of 
gp130, a trans-membrane receptor involved in signal transduction. Cells
which do not express the IL-6r can therefore be stimulated by IL-6 through 
the slL-6r (Peters et af, 1996a; Peters et at, 1996b). Multimeric complexes of 
IL-6 are found in blood associated with plasma proteins and regulate the 
transport and bioavailability of IL-6 (May et al, 1992). These complexes have 
been shown to include the soluble IL-6 receptor (Ndubuisi etal, 1998).
1.4 lnterleukin-6 gene
The IL-6 gene is located at chromosome 7p21 and comprises 5 exons and 4 
introns (Sehgal et al, 1986; Yasukawa et al, 1987). There is a high degree of 
sequence conservation between the human and mouse IL-6 gene, 
particularly in the 5’ promoter region, which is involved in the regulation of IL- 
6 gene expression (Tanabe etal, 1988).
Non-synonymous single nucleotide polymorphisms (SNPs) resulting in an 
amino acid substitution have been identified in exon 1, exon 2 and exon 3. A 
synonymous SNP was identified in exon 3. Thirty-eight intron SNPs have 
also been identified on dbSNP (http://www.ncbi.nlm.nih.gov/SNP). There is a 
variable length polymorphic AT-rich tract in the 3’ untranslated region (UTR) 
of the IL-6 gene (Bowcock etal, 1989).
1.5 interieukin-6 promoter
Early work showed that the 5’ flanking region of the IL-6 gene contains 
regulatory elements (Ray et al, 1988) and an interaction with inducible factors 
(Isshiki et al, 1990), which are activated by other cytokines (tumour necrosis 
factor alpha (TNF-a), interleukin-1 (IL-1), platelet-derived growth factor and
epidermal growth factor) (Faggioli et al, 2004), second messengers and 
viruses (Ray et al, 1988). It is now known that there are multiple regulatory 
elements in the IL-6 promoter (Faggioli et al, 2004). These include NF-IL6, a 
member of the C/EBP (CCAAT/enhancer-binding protein) family (Akira et al, 
1990), AP-1 (a specific DNA sequence that binds c-jun and c-fos 
heterodimers) and NF-kB (Figure 1.2). A glucocorticoid receptor response 
element (GRE) in the IL-6 promoter has also been demonstrated (Ray et al, 
1990) and that activated glucocorticoid receptor represses IL-6 promoter 
activity. A protein-protein interaction between the glucocorticoid receptor 
and NF-IL6 transcription factors is thought to lead to the induction of the 
acute phase protein genes by cytokines and glucocorticoids (Nishio et al, 
1993). NF-KB is activated by the pro-inflammatory cytokines TNF-a and IL-1 
which induce IL-6 (Zhang et al, 1990). Electrophoretic Mobility Shift Assays 
have shown complexes of the p65 subunit of NF-kB, C/EBP and a mutated 
form of c-jun lacking a transactivation domain (Ray and Prefontaine, 1994), 
indicating a functional synergism and the importance of physical location of 
the transcription factors for the induction of IL-6 mRNA expression (Xia et al, 
1997). Stimuli signalled through different pathways are co-ordinated by 
direct protein-protein interactions of NF-IL6 and other transcription factors, 
including NF-kB (Nishio et al, 1993), in the IL-6 promoter (Terry et al, 2000). 
There is an IL-1 response element consisting of a 14bp palindromic 
sequence (ACATTGCACAATCT) in the region of -180 to -123 (Isshiki et al, 
1990). Appendix I contains the annotated IL-6 promoter and gene for 
reference.
1.6 lnterleukin-6 promoter polymorphisms
Three SNPs at position -597, -572 and -174 and a variable AT region at -373 
have been identified in the IL-6 proximal promoter (Figure 1.2) and 
extensively studied in relation to disease association.
NF-IL6
-163 -168
major transcription 
start site >
translation 
NF-kB TATA I NT I ^
consensus sites 
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Figure 1.2. Structure of the IL-6 promoter
Schematic diagram showing polymorphisms at -597, -572, -373 and -174 and 
frans-regulatory elements (GRE glucocorticoid response element, AP-1 c-jun 
and c-fos binding region, MRE multiple response element, CRE cAMP 
response element, NF-1L6 nuclear factor IL-6 and NF-kB complex binding) 
within the IL-6 proximal promoter. The TATA box and transcription start site 
are indicated (adapted from Terry etal, 2000).
Eight IL-6 proximal promoter haplotypes have been identified (Terry et al, 
2000), the four most common of which are shown in Table 1.1. Linkage 
disequilibrium (the relationship between genotypes at a pair of polymorphic 
sites (Carlson et al, 2004)) at the IL-6 locus defined the haplotype GG9/11G,
where individuals carrying the 9/11 allele would usually also have G at -597, 
G at -572 and G at -174.
Haplotype Frequency
-597A -572G 8A/12T -174C 0.36
-597G -572G 10A/11T -174G 0.24
-597G -572G 9A/11T -174G 0.18
-597G -572G 10A/10T -174G 0.12
Table 1.1. Common haplotypes of IL-6 proximal promoter 
polymorphisms
Four common IL-6 promoter haplotypes and the frequency of each in a 
Caucasian population (Terry etal, 2000).
1.7 Polymorphisms and disease
Single nucleotide polymorphisms make up ninety percent of DNA variation in 
the human genome (Collins et al, 1998). Single nucleotide polymorphisms in 
coding or regulatory regions are more likely to cause functional changes in 
gene expression. Mapped SNPs are used as markers for finding functional 
SNPs in the genome, by analysis of linkage disequilibrium over large areas of 
the genome, and this can differ by population groups. An important review 
by Clark (Clark, 2004) makes the case that it is necessary to consider a 
haplotype, and not just a single genotype, when studying the potential of 
candidate genes in disease.
1.8 lnteHeukin-6 promoter polymorphisms and disease
Several groups have sought a link between the circulating plasma levels of
IL-6, disease occurrence, severity or progression and genetic variation. This
section reviews IL-6 expression, promoter polymorphisms and disease
association.
1.8.1 lnterleukin-6 and cardiovascular disease
Atherosclerosis is the result of a chronic inflammatory process (Ross, 1999). 
In an early study of human explants tissue culture supernatants of 
atherosclerotic abdominal aortic aneurysms, IL-6 production was shown to be 
increased when compared to normal aortic tissue (Szekanecz et al, 2004). 
Plasma levels of IL-6 and C-reactive protein were measured, as markers of 
risk for cardiovascular disease, among women participating in the Nurses’ 
Health Study and men participating in the Health Professionals Follow-Up 
Study, and who provided a blood sample at baseline (Pai et al, 2004). 
During the eight or six year follow up respectively, 239 women and 265 men 
had a non-fatal myocardial infarction or fatal coronary artery disease. The 
study demonstrated an increased risk of coronary artery disease associated 
with high levels of circulating IL-6 and CRP at baseline, after adjusting for the 
traditional cardiovascular risk factors of age, smoking, plasma lipid levels and 
the presence or absence of diabetes and hypertension.
A mouse model was developed to investigate the role of IL-6 in 
atherogenesis (Schieffer et al, 2004). Double knockout mice ApoE'^‘IL-6“^‘ 
were fed a normal chow diet over the lifetime of the mice. Serum cholesterol
levels and subsequent atherosclerotic lesion formation were significantly 
increased in the ApoE'^'IL6‘^ ' mice compared with the ApoE'^", wild type and 
IL6‘ ‘^ mice. Contrary to previous information, this study showed that a lifetime 
deficiency of IL-6 enhances the development of atherosclerosis, suggesting 
that baseline IL-6 levels are required for lipid homeostasis and vascular 
remodelling. IL-6 may effect its actions in the atherosclerotic lesion by 
increasing metalloproteinase-13 gene expression through the Janus kinase 
JAK2 cell signalling pathway, AP-1 binding activity and c-jun phosphorylation 
(De la Torre et al, 2005).
In a UK Caucasian population, 132 patients undergoing coronary artery 
bypass graft surgery were genotyped for the AnTn polymorphism by direct 
sequencing (Kelberman et al, 2004). Individuals homozygous for the IL-6 - 
373 9A/11T polymorphism had significantly higher post-operative IL-6 levels 
than 10A/11T homozygotes. This study also reports that the IL-6 promoter - 
373 AnTn polymorphic tract is conserved in length between primate species, 
suggesting that this region is functional, independent of the other single 
nucleotide polymorphic sites within the IL-6 promoter.
Stroke is a debilitating outcome of cardiovascular disease. Stroke incidence 
and severity has been studied in relation to IL-6 promoter polymorphisms 
(Chamorro et al, 2005). Stroke phenotypes was characterised with respect 
to the presence or absence of the IL-6 -174 CC genotype. Lacunar stroke 
affects the deep, penetrating cerebral arteries and often occurs due to 
hypertension. The prevalence of the -174 CC genotype, as determined by
PCR RFLP, was studied in 89 patients with lacunar stroke (19.1%), 82 with 
stroke due to large vessel disease (8.5%), 53 with cardioembolism (7.5%) 
and 49 with idiopathic stroke (14.3%), when compared to a matched control 
group with no history of stroke (n = 105, 8.6%). The -174 CC genotype was 
associated with lacunar stroke (OR 3.22, 95% Cl, 9.09 to 1.12), whereas 
pooling of the patients with non-lacunar stroke did not show any association 
of the -174 CC genotype when compared with the control group (OR 1.01, 
95% Cl, 2.77 to 0.36). The authors propose that the deep cerebral arteries 
may be more susceptible to IL-6-mediated inflammation.
Forty-eight stroke patients recruited within 24hrs of onset were analysed for 
serum levels of IL-6r and s!L-6r and genotyped for the IL-6 promoter 
polymorphisms (Acalovschi et al, 2003). Exclusions were made due to 
infection, malignancy or admission to intensive care. C-reactive protein, 
fibrinogen and serum IL-6 were increased in stroke patients. Serum soluble 
gp130 levels were reduced in the first week after stroke onset but had 
returned to normal levels at follow-up. No difference was observed between 
patients and controls with respect to IL-6r. There was an observed difference 
in the frequency of the GG10/10G IL-6 promoter haplotype between patients 
and controls. The most frequent haplotype, AG8/12C, was associated with 
low serum IL-6 levels in stroke patients. Transfection of the astrocyte-like 
cell line U373 (a cell type important in the study of ischaemic stroke) with 
constructs of the known IL-6 promoter haplotypes showed a significantly 
lower IL-6 induction with the AG8/12C construct in response to an adenosine 
analog, a known stimulus of IL-6 transcription.
Increased levels of the 60kDa heat shock proteins (hsp60) were associated 
with severe risk of atherosclerosis (Pandey et al, 2004). Healthy, male blood 
donors (n=176) were recruited and genotyped for the IL-6-174 G/C SNP 
(Veres et al, 2002). Antibody levels to human hsp60 and Mycobacterium 
bovis hsp65 were determined by ELISA. Carriers of the IL-6 -174 C allele at 
this position had a significantly lower level of anti-hsp60 and anti-hsp65 
antibodies.
Endothelial function was assessed by flow mediated dilatation, in response to 
endothelium-dependent or independent stimulation (Brull et al, 2002). The 
effect of the IL-6-174 G/C alleles on endothelial function was assessed in 
248 healthy adult volunteers. The authors found a significant difference in 
the endothelial-dependent responses in smokers who were homozygous for 
the IL-6 -174 C allele. However, no serum IL-6 measurements were made 
and the authors speculate that the results observed in the smoking group are 
indicative of a more complex set of reactions and not a direct cause-effect.
Atherosclerosis not only affects the heart and brain resulting in heart attack 
and stroke, but can also affect other organ systems. The IL-6 -174 G/C SNP 
may be associated with a protective effect against renal artery occlusion 
(Weger et al, 2005). The frequency of the -174 C allele was significantly 
lower in 182 patients with renal artery occlusion than in 307 matched control 
subjects. Homozygosity for the C allele was associated with an odds ratio of 
0.5 (95% Cl, 0.28 to 0.89) for renal artery occlusion. A large study tested the 
association of known gene variants with acute renal injury following cardiac
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surgery (Stafford-Smith et al, 2005). DNA was isolated from pre-operative 
blood and genotyped by mass spectrometry for 12 candidate polymorphisms. 
Caucasians and African Americans were analysed separately. The IL-6 -572 
C and angiotensinogen -842 C alleles showed a strong association with renal 
injury in Caucasians (p<0.0001). A less stringent application of the criteria 
for significance identified four additional polymorphisms in Caucasians (ApoE 
-448 C, angiotensin receptor I -1166 C and eNOS -894T). The paper draws 
the conclusion that clinical assessment and identification of genetic variation 
could be used to predict post-cardiac surgery renal dysfunction.
However, the role of IL-6 in cardiovascular disease is controversial. For 
example, a study of 57 patients post myocardial infarction showed no 
association with plasma levels of inflammatory markers including TNF-a, 
CRP or IL-6 (Annique et al, 2005). Other studies have similarly shown no 
clear evidence for the involvement of IL-6 promoter polymorphisms in 
cardiovascular risk and myocardial infarction (Bennet et al, 2003). The 
authors do however comment on the finding that serum IL-6 levels are 
increased in cases versus control for men but not for women. In this study 
matched controls for age, sex, smoking, body mass index, physical activity, 
biochemical markers and hormone replacement therapy (in women), suggest 
that the finding of increased serum IL-6 in male patients is associated with 
myocardial infarction.
Increasing evidence supports the hypothesis that acute infections, possibly 
mediated by IL-6, rather than the chronic inflammation identified with
11
atherosclerosis, may be associated with a transient increased risk of 
cardiovascular events. A study based on the United Kingdom General 
Practice Research Database, containing the records of more than 5 million 
patients looked at a total of 20,486 patients with a first myocardial infarction 
and 19,063 patients with a first stroke, who had received the influenza 
vaccine (Smeeth et al, 2004). They concluded that there was no increase in 
the risk of myocardial infarction or stroke in the period after vaccination 
against influenza, tetanus or pneumococcus. However, it was noted that the 
risk of both events were significantly increased during the first 3 days of 
being diagnosed with systemic respiratory tract infection and to a lesser 
extent in those patients diagnosed with a urinary tract infection. The risk 
decreased in the following weeks. In this study, circulating IL-6 levels were 
not measured.
In a small study, subjects were vaccinated with Salmonella typhii to test the 
role of IL-6 -174 G/C in induction of IL-6 in vivo (Bennermo et al, 2004b). 
Individuals were homozygous for the -174 C (n=20) or G (n=18) alleles. 
Subjects homozygous for the G allele showed significantly increased serum 
IL-6 levels at 6, 8 and 10 hours after vaccination. However, the results do 
show large error bars, possibly due to the small sample size, and might 
suggest the additional importance of haplotype in looking for disease 
association.
Table 1.2 is a summary of the IL-6 promoter genotype with atherosclerotic 
disease.
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1.8.2 Interleukin-8 and rheumatoid arthritis
Systemic onset juvenile chronic arthritis is a chronic, autoimmune, 
inflammatory disease with a fever spike once or twice a day, usually at the 
same time. It has been shown that serum lL-6 levels increase in line with the 
fever spike and decrease as the body returns to normal temperature. The 
authors propose that the regulation of lL-6 differs between patients and 
unaffected individuals and that dysregulation of lL-6 production is a function 
of lL-6 promoter polymorphisms (Fishman et al, 1998). This study used a 
reporter gene assay to study the effect of LPS or lL-1 in HeLa cells 
transfected with either the lL-6 promoter -373 8A/12T, -174 C or the -373 
8/12, -174 G construct. A significant reduction in the response to LPS and 
lL-1 was observed in cells transfected with the -174 C allele compared to the 
G allele. In a Caucasian group of patients with juvenile chronic arthritis, there 
were significantly less of the lL-6 -174 GO genotype than in the control group, 
indicating that the -174 GO genotype may offer a protective effect in 
development of the disease.
In addition, disease outcome was correlated with genotype of the pro- 
inflammatory cytokines TNF-a, lL-6 and IFN-y and the anti-inflammatory 
cytokines lL-10 and TGF-p in juvenile rheumatoid arthritis (Oen et al, 2005). 
Genotypes were determined for patients with juvenile rheumatoid arthritis 
who were participating in a long-term outcome study. In a multivariate 
analysis the lL-6 -174 GG genotype was positively correlated with pain, whilst 
an association of the TGF-p codon 25 GG genotype showed a protective
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effect against joint space narrowing. The results were inconclusive as to the 
usefulness of these SNPs as early prognostic indicators of disease.
In a study of juvenile idiopathic arthritis the association with IL-6 promoter 
polymorphism -174 GC was determined (Ogilvie ef al, 2003). Three cohorts 
from UK, American and French families were recruited. The IL-6 -174 SNP 
was genotyped by RFLP, heteroduplex analysis or allelic discrimination. The 
IL-6 -373 AnTn polymorphism was determined by DNA sequencing. When 
the data from all three cohorts were taken together, a significant association 
between occurrence of arthritis in patients and the IL-6 -174 G allele was 
found (p=0.04). When subsets of the systemic juvenile idiopathic arthritis 
families were compared, the excess transmission of the -174 G allele was to 
patients more than five years of age at disease onset (p=0.007). No 
association was observed between the AnTn alleles or the -174 / -373 AnTn 
haplotypes. The US cohort had a similar significant transmission.
In a follow-up to this study in 2005 (Fife et al, 2005), this work was expanded 
by looking at other SNPs and polymorphisms in the IL-6 promoter. In 
addition to the -174, -572, -597 SNPs, the authors also analyzed 103 patients 
and one or both parents, for a SNP at -1363 G/T and a newly reported 
insertion/deletion -1480 [CT]. An over represented haplotype was identified 
in affected individuals, a 4-marker haplotype -1480[+CT], -1363G, -572G, - 
174G.
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1.8.3 lnterleukîn-6 and obesity
IL-6 is produced by adipocytes (Vicennati et al, 2002) and circulating IL-6 is 
increased in obese individuals. The IL-6 -174 G/C and IL-6 -572 G/C 
promoter polymorphisms were studied in a largely male, hypertensive 
Swedish population (mean age 57 years), to investigate the association 
between these single nucleotide polymorphisms and obesity (Wernstedt et ai, 
2004). Body mass index, serum leptin levels, serum IL-6 levels. C-reactive 
protein, fasting blood glucose and blood lipid levels were measured. A 
control group of younger non-obese females was also studied. In both 
groups the IL-6 -174 C allele (/=0.46) was associated with higher body mass 
index and higher serum leptin levels. Obese patients undergoing gastric 
banding surgery (n=65) were genotyped for polymorphisms in leptin, IL-6 and 
adiponectin genes (Poitou et ai, 2005). Serum concentrations of leptin, IL-6 
and adiponectin and body mass index were measured before surgery and at 
follow up one year later. Weight loss following the surgery was associated 
with an increased circulating IL-6 concentration in carriers of the IL-6 -174 
CC genotype. Carriers of the IL-6-174 CG or GG alleles showed a decrease 
in circulating IL-6 concentration. This suggests a role for IL-6 in body weight 
homeostasis.
In Swedish study of eighty-five men were genotyped for the IL-6 -174 G/C 
SNP and IL-6 gene expression was measured in subcutaneous adipose 
tissue. Higher fasting insulin levels and greater insulin resistance was 
observed in IL-6 -174 G allele carriers. Circulating adiponectin levels were 
lower in G allele carriers, whilst there was a significant increase in IL-6 gene
16
expression in adipose tissue. There was no difference between IL-6 -174 G 
or C allele carriers in plasma IL-6 (Yang et al, 2005). This suggests a tissue- 
specific regulation of IL-6 gene expression.
1.8.4 Interleukin-6 and type 2 diabetes mellitus
In a recent study, 188 cases versus 376 nested controls were drawn from a 
population study in Germany (Mohlig et al, 2004). Cases were free of 
diabetes at baseline but had developed the disease at follow up. Individuals 
with a body mass index greater than 28 and with the IL-6 -174 CC genotype 
had a five times greater risk of developing type 2 diabetes mellitus compared 
with other genotypes. Patients in this group were encouraged to lose weight 
to reduce the risk of developing diabetes.
In a Finnish study of 490 overweight patients with impaired glucose 
tolerance, genomic DNA was genotyped for SNPs in the TNF-a and IL-6 
genes (Kubaszek et al, 2003b; Kubaszek et al, 2003a). Subjects with both 
the TNF-a -308A and IL-6 -174C alleles showed a greater risk of developing 
type 2 diabetes.
In a Danish study (Hamid et al, 2005), 6,164 subjects from the Inter99 cohort 
in the prevention of cardiovascular disease were recruited as controls 
provided that they had normal glucose tolerance and had no signs of 
metabolic syndrome, as defined by the World Health Organisation. Cases of 
diabetes were recruited from a diabetes clinic (n=1389). Cases and controls 
were genotyped for the IL-6 promoter SNPs at position -597, -572 and -174.
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The IL-6 -597 and IL-6 -174 SNPs were shown to be in strong linkage 
disequilibrium (0.95). The IL-6 -174 G allele was associated with insulin 
resistance and the IL-6 -572 C allele was associated with increased serum 
insulin release during the oral glucose tolerance test. The authors report that 
the -597 G, -572 C, -174 G haplotype was more commonly associated with 
the type 2 diabetes patients. This is an unexpected finding as previous 
studies of haplotype frequencies show that this haplotype is uncommon 
(frequency = 0.05) (Terry et al, 2000). A study from northern Spain recruited 
Caucasian subjects for a prospective study of the IL-6 -174 G/C SNP and 
insulin sensitivity (Fernandez-Real et ai, 2000). Following an oral glucose 
tolerance test the area under the curve of serum glucose concentrations 
showed an allele-specific effect (CC 6.3mmol/l, CG 9.3mmol/l, GG 
9.7mmol/l).
A large meta-analysis covering more than 20,000 participants in 21 studies 
from eight European countries showed that individuals carrying either the IL- 
6 -174 GC or CC alleles were associated with a decreased risk of diabetes. 
There was no association with the IL-6 -572 G/C polymorphism (Huth et al,
2006). Furthermore, an association was demonstrated between metabolic 
syndrome and pre-diabetes in IL-6 -174 C allele carriers (Stephens et al,
2007).
1.8.5 Interleukin-6 and inflammatory bowel disease
The differential production of cytokines linked to SNPs in the promoter
regions of cytokine genes has prompted studies of association in known
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chronic inflammatory diseases. In a study of 193 patients with inflammatory 
bowel disease, including 138 with Crohn’s disease and 55 with ulcerative 
colitis, no association was found between the cytokine gene polymorphisms 
studied and inflammatory bowel disease susceptibility, when compared to 92 
controls (Cantor et al, 2005). However, the authors do note an association 
between disease phenotype and the site of Crohn’s disease, and the IL-6 - 
174 G/C polymorphism. Patients with ileocolonic Crohn’s disease were more 
likely to carry the IL-6 -174 GG genotype than non- ileocolonic Crohn’s 
disease. Patients with ileal Crohn’s disease were more likely to possess the 
IL-6 -174 GC genotype compared to those with non-ileal disease. An 
increased number of Crohn’s disease patients with isolated colonic disease 
possessed the IL-6 -174 CC genotype compared to those with non-isolated 
colonic disease.
1.8.6 Interleukin-6 and aging
Chronic inflammation is associated with several neurodegenerative diseases 
of aging, including Alzheimer’s disease, Parkinson’s disease, non- 
Parkinson’s dementia and age-related macular degeneration, possibly due to 
genetic variation and dysregulation of the balance between IL-6 and IL-10 
(Caruso et al, 2004; McGeer and McGeer, 2004).
In a study of 362 eighty year old subjects in Denmark (Bruunsgaard et al,
2004), of whom 29 were excluded due to illness, the authors found an 
association of the IL-6 -174 C allele with mortality in octogenarians. This 
association was complex and interacted with smoking status. The IL-6 -174
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GG genotype showed a protective effect against age-related pathology. In a 
similar study in Denmark, this finding is corroborated, as the authors 
observed a significant increase in the IL-6 -174 GG genotype in longevity 
(Christiansen et al, 2004).
Interestingly, a study conducted in Italy attempted to reproduce previous 
work on the effect of IL-6 -174 CC genotype on longevity (Capurso et al,
2004). However, the authors did not show any association with the IL-6 -174 
C polymorphism and longevity, which they speculate could be related to 
environmental differences between the populations in Denmark and Italy.
1.8.7 Interleukin-6 and other studies
In other studies of the IL-6 -174 SNP, it has been shown that this single 
nucleotide polymorphism is associated with increased production of IL-6 from 
leukocytes stimulated ex vivo with lipopolysaccharide for 24 hours (Rivera- 
Chavez et al, 2003). Leukocytes from individuals homozygous for the G 
alleles at IL-6 -597 and IL-6 -174 (that is, -597 G, -174 G) showed the 
greatest production of IL-6, whilst the cells from individuals homozygous for 
the A allele at IL-6 -597 and the C allele at IL-6 -174 (-597 A, -174 C) showed 
the lowest response.
Chronic obstructive pulmonary disease is characterized by an abnormal 
inflammatory reaction to inhaled particles and fumes. Promoter 
polymorphisms in genes coding for the inflammatory markers TNF-a, TNF-p, 
IL-6 and IL-10 were studied in a case-control study, of 113 patients
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diagnosed with chronic obstructive pulmonary disease and 113 age, sex and 
smoking-matched patients hospitalised with severe coronary heart disease 
without pulmonary disease and 243 healthy population controls (Seifart et al,
2005). The results did not show any significant differences in the genotype 
distribution of the tested SNPs between the chronic obstructive pulmonary 
disease patients and matched coronary heart disease patients. However, a 
comparison with the population controls revealed a significant correlation with 
the IL-10 -1082 G allele being more common in the chronic obstructive 
pulmonary disease patients (OR 1.66, 95% Cl, 1.01 to 2.75).
Patients with pulmonary hypertension and chronic obstructive pulmonary 
disease had greater serum IL-6 levels than controls and were associated with 
the IL-6 -174 GG genotype (Eddahibi et al, 2006). Moulds are associated 
with incidence of asthma and allergy. There was an IL-6 / IL-10 imbalance 
as measured by ELISA in cell culture supernatants from the human Mono- 
Mac 6 cell line, stimulated with mycotoxins with or without LPS treatment 
(Johannessen et al, 2005). In a group of chronic obstructive pulmonary 
disease cases versus matched controls, there was an association with the IL- 
10 1082 G allele, but not IL-6 174, and decreased IL-10 levels (Seifart et al,
2005). These data point to the contribution of IL-6 / IL-10 homeostasis in 
regulating inflammation.
Glucose-6-phosphate dehydrogenase deficiency is associated with 
resistance to the malaria parasite in African American populations. Seventy- 
one percent of glucose-6-phosphate dehydrogenase deficient men studied
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(n=111) carried the IL-6 -174 G allele. The presence of the IL-6 -174 G 
allele, together with the presence of the IL-10 -592 A and IFN-y +874 A 
allele, is predominant in individuals with ancestry from malaria-endemic 
regions (Upperman et al, 2005), suggesting a protective effect of these 
polymorphisms.
Protein gp41 isolated from HIV and incubated with monocytic THP-1 cells 
resulted in rapid IL-6 gene expression which was downregulated by 
endogenous IL-10 (Takeshita et al, 1995). The cells were cultured over 7 
days. IL-6 increased over days one to four and then IL-10 increased whilst L- 
6 decreased. This was consistent with data from CD4+ T cells (Weimer et al, 
1998).
The cause of recurrent spontaneous abortions are largely unexplained. A 
case-control study in a southern Brazilian population of 57 women with 
recurrent spontaneous abortions showed an increased frequency of the IL-6- 
174 CC genotype (18%) when compared with 74 matched controls (4%) (Von 
Linsingen, Bompeixe and Bicalho, 2005).
A small study of 29 patients with renal cell carcinoma and 50 healthy controls 
suggests that the IL-6 -174 CC genotype may be protective for renal cell 
carcinoma (Basturk et al, 2005).
The rare IL-6 promoter haplotype -597G, -572C, -174G in a Jamaican 
Caribbean population was associated with susceptibility to the human T
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lymphotrophic virus type I among children born to HTLV l-positive mothers 
(Brown et al, 2006).
Early studies have shown that oestrogens inhibit TNF-a-induced IL-6 
expression (Galien et al, 1996) and that 17p-estradiol inhibits IL-6 expression 
(Pottratz et al, 1994), mediated by the C/EBP and NF-kB sites in the IL-6 
promoter (Stein and Yang, 1995), possibly in a tissue-specific manner. This 
is important for the study of osteoporosis and bone mineral density, 
particularly in post-menopausal women (Ferrari et al, 2004; Moffett et al, 
2004), where lifestyle and dietary factors influenced the effect of IL-6 
promoter polymorphism -174 G/C. Bone mineral density is lowest amongst 
women with the IL-6 -174 GG genotype compared to the CC genotype.
A Danish study of young females showed an association of -174 C with type I 
diabetes mellitus, which decreases with age possibly due to the increase of 
17p-estradiol with puberty (Kristiansen et al, 2003), and this was confirmed 
by a more recent study (Gillespie et al, 2005) of 521 female patients recruited 
from the UK-BOX study diagnosed with type I diabetes before the age of 21, 
although the Danish female IL-6-174 CC population have an earlier age of 
onset.
1.8.8 Interleukin-6 and population studies
It has previously been shown that population differences account for some of 
the contradictory information on the effects and correlation of the IL-6
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promoter polymorphisms. In particular, studies on Japanese populations 
vary from Caucasian population studies.
Japanese individuals with chronic periodontitis, n=112, and non-CP controls 
(n=77) were genotyped for four SNPs in the IL-6 promoter (-597, -572, -190, - 
174) and the -373 AnTn polymorphic tract (Komatsu et al, 2005), in order to 
investigate an association of the IL-6-373 AnTn polymorphism with 
inflammatory disease and serum IL-6 levels. The -190 SNP is not found in 
Caucasian populations. In this study, all the subjects were homozygous for 
the -597 G allele, -190 C allele and -174 G allele. The -572 and -373 
polymorphisms were in Hardy Weinberg Equilibrium and in linkage 
disequilibrium. The frequency of the IL-6 -373 9A 11T allele was found to be 
significantly higher in individuals without chronic periodontitis. Serum IL-6 
levels assessed by ELISA were shown to be lower in association with the - 
572 G and -373 9A 11T haplotype. It is suggested that in this population the 
-572 G, -373 9/11 haplotype could be associated with a decreased risk of 
chronic periodontitis A meta-analysis of prospective and retrospective 
studies showed that periodontal disease may increase the risk of 
cardiovascular disease and stroke (Meurman et al, 2004).
1.8.9 Studies showing no association with IL-6 promoter 
polymorphisms
The search for prognostic markers for disease outcome is ongoing. The 
number of studies showing no association between cytokine gene 
polymorphisms and disease outcome is almost as large as the number of
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studies published which show one or other SNP may be significantly 
associated with disease risk and/or outcome. I include the following 
examples of this negative association.
Researchers genotyped paediatric patients on the heart transplant list for 
end-stage ventricular failure due to cardiomyopathy or congenital heart 
disease (Webber et al, 2002). Single nucleotide polymorphisms in TNF-a, IL- 
10, IL-6, TGF-p and IFN-y were assessed by PCR RFLP. Patients with 
ventricular failure after transplantation for dilated cardiomyopathy (n=37) or 
congenital heart disease (n=34), fifteen patients transplanted for structural 
disease, such as hypoplastic left heart syndrome without ventricular failure, 
and an additional eight patients with congenital cardiomyopathy, were 
compared to data from healthy children. No differences in genotype 
distribution between the groups was found, although this should not be 
surprising as cardiomyopathy is not an atherosclerotic disease.
A study in Chinese children with immune thrombocytopenic purpura (fifty 
children with acute immune thrombocytopenic purpura and thirty children with 
chronic immune thrombocytopenic purpura) versus one hundred healthy 
individuals failed to show an association with the IL-6 -572 G/C 
polymorphism (Wu et al, 2005). In the same study a comparison of IL-4 and 
IL-10 SNPs with healthy controls showed significant differences. The 
presence of the IL-4 and IL-10 SNPs may increase the risk of developing 
childhood chronic immune thrombocytopenic purpura.
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In a study published in 2004 (Bennermo et al, 2004a), the authors comment 
on the limitations of their and other studies and that the presence or absence 
of IL-6 -174 G/C alleles in particular is not predictive. In this study, a 
borderline association was reported between the IL-6 -572 G polymorphism 
and a prediction of cardiovascular risk.
A meta-analysis of 5,383 diabetes cases and 12,069 controls showed no 
association with the IL-6 -174 G/C SNP. The authors also looked at seven 
SNPs, three 5’ promoter, one in intron 3, one in exon 5 and two in 3' UTR 
and found no association in either men or women as single polymorphisms or 
as haplotypes with type 2 diabetes mellitus. All the SNPs were in linkage 
disequilibrium (O' greater than 0.95) and there was no association with 
plasma IL-6 levels (Qi etal, 2006).
An important point is made by the authors of a study where no association 
was found between the IL-6-174 G/C, IL-10-1082 G/A and TGF(3-509 C/T 
polymorphisms and the premature onset of ischaemic heart disease in an 
Irish population (McGlinchey et al, 2004). Future work will have to pay 
attention to both large scale case versus control studies and transmission 
disequilibrium test, or family-based methods, to ensure consistency of 
results.
From the literature it is becoming clear that, in the study of the IL-6 promoter, 
the haplotype and not just a single base change, could affect an individual’s 
IL-6 response. This suggests an important level of regulation influenced by
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haplotype (Terry et al, 2000; Acalovschi et al, 2003). The contradictory 
results of disease association with IL-6 promoter polymorphisms arise not 
just from gene-environment interactions in different population groups, but 
also from the small sample size in some studies, the lack of disease severity 
and progression stratification when comparing disease-polymorphism 
association, and the emerging importance of studying a haplotype to assess 
functional genomics.
1.9 Hypothesis
IL-6 proximal promoter haplotype influences the normal ex vivo individual 
macrophage inflammatory response.
1.9.1 Objectives
1. To establish the THP-1 cell line as a monocyte-macrophage model of the 
IL-6 inflammatory response.
2. To quantitate IL-6 gene expression in primary monocyte-derived 
macrophages from healthy individuals of known IL-6 proximal promoter 
haplotype.
3. To investigate possible mechanisms of IL-6 proximal promoter activation.
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Chapter 2 Materials and Methods
2.1 Suppliers
Suppliers used are listed below unless othen/vise stated in the text.
Abgene 
Agar Scientific 
Applied Biosystems 
Biotage
Fisher Scientific
Graph Pad Software
Invitrogen
MWG-Biotech
Nanodrop Technologies
New England Biolabs
NT-MDT
Promega
Qiagen
R&D Systems
Sigma-Aldrich
Whatman
Epsom, UK 
Essex, UK 
California, USA 
Uppsala, Sweden 
Loughborough, UK 
California, USA 
Paisley, UK 
Ebersberg, Germany 
Wilmington, USA 
Herts, UK 
Moscow, Russia 
Southampton, UK 
Crawley, UK 
Abingdon, UK 
Dorset, UK 
Maidstone, UK
2.2 Ethics
This study was approved by the NHS South West Surrey Local Research 
Ethics Committee (04/01909/19) and the Advisory Committee on Ethics of 
the University of Surrey (EC/2004/58/SBMS).
2.3 Recruitment of volunteers
Twenty-seven healthy volunteers (n=11 male, n=16 female) working or 
studying at the University of Surrey or the Royal Surrey County Hospital and
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who had previously participated in a study to investigate inflammatory factors 
in the metabolic syndrome were recruited. In the initial study, lipids, fasting 
glucose and C-reactive protein were measured in these volunteers and only 
those whose serum levels of these analytes were within the reference range 
for healthy subjects were invited to participate in this study, to avoid those 
with incipient disease. Any individuals with abnormal levels were referred to 
specialists as part of the previous study.
2.4 Experimental design
Volunteers were genotyped for the IL-6 promoter polymorphisms. Individuals 
of known haplotype were recalled for ex vivo culture of monocyte-derived 
macrophages. IL-6 gene expression, promoter chromatin remodelling and 
secondary structure were assessed in the THP-1 cell line and primary 
monocyte-derived macrophages.
2.5 Genomic DNA extraction
Genomic DNA was extracted from white blood cells of consented healthy 
volunteers using Genecatcher (Invitrogen), according to the manufacturer’s 
instructions. Briefly, DNA is captured from lysed cellular matter using 
positively charged magnetic beads at low pH and eluted into TE buffer at 
pH8.5.
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2.6 Genotyping fo r IL-6 promoter polymorphisms
Volunteers were genotyped for seven IL-6 promoter polymorphisms as well 
as two intron polymorphisms (Table 2.1). The THP-1 cell line was also 
genotyped for the IL-6 proximal promoter polymorphisms.
In addition to the four proximal polymorphisms, three distal promoter 
polymorphisms at position -1586, -1480 and -1363 were included. The single 
nucleotide polymorphism at -1586 was previously validated on dbSNP 
(http://www.ncbi.nlm.nih.qov/proiects/SNP/). The -1480in/del and -1363 
single nucleotide polymorphisms were included in an analysis of juvenile 
systemic arthritis trio families (Fife et al, 2005). Two non-promoter SNPs 
were also genotyped in intron 2 and intron 3 of the IL-6 gene as these were 
not in linkage disequilibrium with the promoter polymorphisms. All 
polymorphisms were in Hardy Weinberg Equilibrium, that is, there was no 
deviation from the expected frequency. Frequency of the polymorphisms 
were consistent with reported values.
The IL-6 proximal promoter haplotypes were determined by visual 
assessment using Clark’s Algorithm and confirmed by HaploView (version 
3.32) (Barrett et al, 2005) (http://www.broad.mit.edu/mpq/haploview/) and 
SNPStats (Sole etal, 2006)
(http://bioinfo.iconcoloqia.net/index.php?module=Snpstats).
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2.6.1 Restriction fragment length polymorphism (RFLP)
RFLP assays were used to genotype the IL-6 promoter -1480, -597, -572 and 
-174 SNPs. The assays for -597, -572 and -174 were described previously 
(Khwaja, PhD thesis, Oxford 2005), whilst the assay for the -1480 was 
developed for this project, according to Table 2.2. The primer sequences 
for all PCR reactions are listed in Table 2.3. All PCR reactions were carried 
out in 25p! reactions.
The assay for the IL-6 -1480 SNP is described. A PCR product of 197bp 
was digested to fragments of 153bp and 44bp with BsmA I (New England 
Biolabs) which recognizes the site 5’-GTCTC-3’. The restriction enzyme 
digestion condition was optimized in a 25pl reaction volume for 3 hours at 
55°C, according to the manufacturer’s recommendations.
2.6.2 Fragment analysis
The IL-6 -373 AnTn polymorphism was genotyped using a method of 
fragment size analysis (Khwaja and Green, 2006) at the Wellcome Trust 
Centre for Fluman Genetics, Oxford. This method allows differences in 
length of one base pair to be resolved.
A structural motif ‘q TTTCTT’ was included on the 5’ end of the forward PCR 
primer to ensure complete non-templated adénylation of the 3’ end of the 
reverse PCR strand. A fluorescently labelled reverse primer was used to 
label the PCR product. The fluorescently labelled product was digested with
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Tsp509 I, which recognizes the site ^AATT, and the fragment lengths 
analysed by capillary electrophoresis.
2.6.3 PyroSequencing
PyroSequencing (PSQ) is sequencing by synthesis. A complementary strand 
is built up with the addition of dNTPs in sequence. Each incorporated dNTP 
leads to the release pyrophosphate which is converted to ATP. ATP 
mediates the conversion of luciferin to oxyluciferin by luciferase. This visible 
light signal is detected by a camera and is seen as a peak on the 
accompanying pyrogram, the height of which is proportional to number of 
nucleotides incorporated.
PyroSequencing assays were used to genotype the IL-6 promoter -1586 and 
-1363 SNPs, and the IL-6 intron 2 and intron 3 SNPs. The assay for -1363 
was described previously (Fife et al, 2005). Assays for -1586 and intron 2 
and 3 were designed using the online SNP Primer Design from 
PyroSequencing AB version 1.0.1 (Biotage). The sequences of the PCR 
primers and PSQ sequencing primers are listed in Table 2.4.
A short region of DNA around each SNP of interest was amplified by PCR 
using a biotinylated primer in a 50pl reaction volume from lOng genomic 
DNA. Biotinylated PCR product (40pl) was captured on 3pl streptavidin­
coated sepharose beads (Amersham) with 37pl binding buffer (Biotage) at 
room temperature by shaking for 5 minutes and immediately captured onto 
the probe tips of the vacuum tool.
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The captured beads and PCR product were denatured by flushing for 5 
seconds each with 70% EtOH (v/v) and dénaturation buffer (0.2M NaOH) and 
washed twice in washing buffer (Biotage).
The template DNA was released into 40pl annealing buffer (Biotage) with 5pl 
sequencing primer (10pmol/pl) in a pyrosequencing 96 well plate. The 
sequencing primer was annealed to the PCR product for 2 minutes at 80°C 
and cooled to room temperature for 5 minutes and transferred to the PSQ96 
for genotyping.
The sequence around the SNP was input into the PSQ96 software which 
calculated the dispensation order of the dNTPs (dATPaS, dCTP, dGTP, 
dTTP), enzyme (DNA polymerase, ATP-sulfurylase, luciferase, apyrase) and 
substrate (luciferin, adenosine 5' phosphosulfate) reagent volumes required 
for each assay depending on the sequence and the number of samples.
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2.7 THP-1 cell line culture
THP-1 monocytic cells were cultured in suspension at 37®C, 5% CO2 in a 
humidified incubator with RPMI1640 with Glutamax I (stabilized essential 
amino acid L-glutamine) (Invitrogen), 10% (v/v) heat inactivated foetal bovine 
serum (FBS) (Invitrogen) and 1% (v/v) penicillin-streptomycin (5000U/ml 
penicillin G sodium, 5000pg/ml streptomycin sulphate) (Invitrogen). The 
stocks of THP-1 cells tested clear for Mycoplasma infection {M. arginini, M. 
hyorhinis, M. laidlawii, M. orale).
2.7.1 Differentiation of THP-1 cells
THP-1 monocytic cells (passage 2 to 4) were differentiated to macrophage­
like cells by phorbol myristate acetate (PMA) (Tsuchiya et al, 1982) as 
follows: the cells were pelleted by centrifugation at lOOOrpm for 5 minutes at 
room temperature, washed with 50ml sterile PBS and counted using a 
haemocytometer. The cells were resuspended in RPM11640 with Glutamax 
I, 10% (v/v) FBS and 1% (v/v) penicillin-streptomycin (5000U/ml penicillin G 
sodium, 5000pg/ml streptomycin sulphate) to a density of 4 x 10® cells/ml, 
seeded at 2.4 x 10® cells per well and cultured with PMA at a final 
concentration of 10nM for 72 hours.
2.7.2 Stimulation of THP-1 cells
Monocytic (in suspension) and macrophage-like (adherent) THP-1 cells at a 
density of 2.4 x 10® cells per well in a 24 well tissue culture plate were treated 
with either 2.5ng/ml IL-1(3, lOOU/ml IFN-y or 100ng/ml IPS (Table 2.5).
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Interleukin-1 (3 Interferon-Y LPS
Supplier : R&D 
Systems, UK
Supplied as 5pg 
lyophilised.
Add 5ml sterile 
PBS/0.1% BSA sterile 
filtered.
Divided into aliquots 
and stored at -20°C at 
1ng/pl.
Use at 2.5ng/ml 
medium in the well.
Supplier : R&D 
Systems, UK
Supplied as lOOpg 
lyophilised.
Add 10ml sterile 
PBS/0.1% BSA sterile 
filtered.
Divided into aliquots 
and stored at -20°C at 
lOpg/ml.
Use at lOOU/ml medium 
in the well where 1 pi = 
100U.
Supplier : Sigma- 
Aldrich, UK
Strain 0127:B8
Supplied as Img.
Reconstitute with sterile 
PBS.
Divided into aliquots 
and stored at -20°C at 
1 mg/ml.
Use at 100ng/ml 
medium in the well.
Table 2.5, Inflammatory stimuli used for inducing IL-6 in THP-1 cells
The table summarises the inflammatory stimuli and concentrations used in 
the treatment of THP-1 cells to induce IL-6.
2.7.3 Statin treatment
Stock concentrations of 20mM of pravastatin sodium (Sigma-Aldrich) and 
atorvastatin calcium (gift from Dr Graham Smith, AstraZeneca) were 
prepared in 100% DMSO and stored at -20°C. The statins were diluted in 
cell culture medium to a final concentration of IpM, 5pM and 20pM in 0.1% 
(v/v) DMSO. The untreated control was 0.1% DMSO (v/v) in cell culture 
medium.
2.8 Extraction of RNA
Cells were lysed using TRIzol (Invitrogen), a phenolic compound, at a 
concentration of 1ml/10cm^ and the total RNA extracted according to the
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manufacturer’s instructions by chloroform phase separation and isopropanol 
precipitation.
Total RNA was resuspended in 20pl DEPC-treated water, by gentle tip 
mixing. Quantitation and A260/A280 ratio was determined using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). The RNA 
was treated with DNase I (Promega) according to the manufacturer’s 
instructions, to remove any DNA contamination, divided into aliquots and 
stored at -80°C.
2.9 Quantitative PGR (QPCR)
Total RNA extracted from cells was used to measure gene expression levels 
in a one-tube, two-step Sybr Green system. The reverse transcriptase 
enzyme was active at 50°C and the Taq polymerase was activated at 95°C.
2.9.1 Primer design
Primers for the quantitative PCR step were designed previously (Khwaja, 
PhD thesis, 2005, Oxford). The IL-6 primer pair spanned an intron-exon 
boundary to ensure the quantitation of mRNA expression and not genomic 
DNA.
The MLN51 primer pair flanked a large intron to ensure that only specific 
mRNA expression products were quantitated. The primer sequences were 
as follows :
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I L-6_LH 5’-CTA GAT TCT TTG COT TTT TCT GC-3’
IL-6_RH 5’-GAT TCA ATG AGG AGA CTT GCC-3'
MLN51_LH 5’-CAA GAG TGC TGA GGA GTC GG-3’
MLN51_RH 5’-TCA TTA GCT TCT GAT TTC AG-3’
2.9.2 QPCR method
RNA was diluted in RNase-free water to 20ng/3jjl. All RT-QPCR reactions 
were carried out in 12.5pl reaction volume using the QuantiTect Sybr Green 
RT-PCR kit (Qiagen), according to the manufacturer’s instructions. The 
cycling parameters were as follows : 50*C for 30 minutes, 95°C for 15 
minutes, 95°C for 15 seconds followed by 58°C for 1 minute for 40 cycles. A 
melt curve of the QPCR product was produced for each reaction to show the 
specificity of the reaction.
2.10 Measurement of !L-6 in tissue culture supernatants and plasma
Supernatants were collected from THP-1 cells and primary monocyte-derived 
macrophages in culture. The supernatants were divided into aliquots and 
stored at -80°C.
Plasma was separated from whole blood by centrifugation at 1500rpm (500g) 
for 20 minutes at room temperature. The white blood cell layer (buffy coat) 
was removed for genomic DNA extraction. The plasma was removed, 
divided into aliquots and stored at -20°C.
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2.10.1 IL-6 high sensitivity ELISA
IL-6 protein was measured in duplicate in cell culture supernatants and 
plasma using the QuantiGlo Chemiluminescent sandwich ELISA kit (R&D 
Systems), according to the manufacturer’s instructions. A standard curve 
ranging from 0.48pg/ml to 30,000pg/ml was produced from recombinant 
human IL-6 according to the manufacturer’s instructions
2.11 Primary monocyte-derived macrophage culture
2.11.1 Isolation of mononuclear cells from whole blood
Blood (40ml) was collected from the volunteers by venepuncture, into EDTA 
coated tubes to prevent coagulation. The blood was immediately diluted 1:1 
with sterile PBS at room temperature. Diluted blood was layered onto an 
equal volume of Histopaque-1077 (Sigma-Aldrich) and the peripheral 
mononuclear cells isolated by density gradient centrifugation, according to 
the manufacturer’s instructions.
The mononuclear cell pellet was resuspended in warmed 5ml serum-free 
medium RPM11640 with GlutaMax I (Invitrogen), 1% (v/v) penicillin- 
streptomycin (5000U/ml penicillin G sodium, 5000pg/ml streptomycin 
sulphate) (Invitrogen).
Viable cells were counted using 0.4% (v/v) Trypan blue exclusion (Invitrogen) 
in a haemocytometer. Cells were seeded at a density of 2 x 10® cells/well in a 
24-well plate and cultured for 2 hours to allow adherence. After 2 hours the 
medium was removed and replaced with RPMI1640 with Glutamax I, 10%
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(v/v) FBS, 1% (v/v) penicillin-streptomycin (5000U/ml penicillin G sodium, 
5000pg/ml streptomycin sulphate).
2.11.2 Ex vivo primary cell culture
The primary cells were cultured for 8 days in RPMI1640 with Glutamax I, 
10% (v/v) FBS, 1% (v/v) penicillin-streptomycin, at 37°C, 5% CO2 in a 
humidified incubator. The medium was replaced daily for 4 days and then at 
day 6 and at day 8 prior to stimulation, when the monocytes had 
differentiated into macrophages (Kaplan and Gaudernack, 1982; Ohyama et 
al, 2000; Malaguarnera et al, 2005). The cells were then stimulated as 
described for the THP-1 cells in section 2.7.2.
2.12 Chromatin accessibility real time PCR (CHART-PCR)
Briefly, intact nuclei were extracted from cells in culture. The nuclei were 
digested with DNase I, which preferentially digests regions of chromatin that 
are more open as a result of active transcription (Rao et al, 2001; 
Brettingham-Moore et al, 2005; Weinmann et al, 1999). Quantitative PCR 
was used to measure the amount of DNA no/digested by DNase I, that is the 
condensed, /nactive chromatin, across the IL-6 promoter, as summarised in 
Figure 2.1.
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DNase I  
digestion
Less PCR product
No DNase I  
digestion
Open 
Euchromatin
Closed 
Heterochromatin
More PCR product 
Figure 2.1. Summary of CHART-PCR assay
DNase I preferentially digests regions of open chromatin resulting in less 
product as determined by QPCR. Conversely, in closed chromatin there is 
no accessibility to DNase I and consequently more QPCR product.
2.12.1 Nuclei extraction
Intact, functional nuclei were extracted following lysis of the cell membranes 
and recovery of the nuclear fraction by centrifugation, using the Nuclei EZ 
preparation kit (Sigma-Aldrich). The manufacturer’s instructions were 
followed but scaled down to extract nuclei from 2x10® cells, as described 
below.
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Adherent cells in a monolayer were washed with 1ml cold sterile PBS and 
lysed with 400pl Nuclei EZ lysis buffer. The lysed cells were transferred to a 
1.5ml tube and incubated on ice for 5 minutes.
Cells cultured in suspension were pelleted by centrifugation at 500g at 4°C 
for 5minutes. The supernatant was discarded and the pellet washed once 
with ice-cold PBS before lysing in 400pl Nuclei EZ lysis buffer on ice for 
minutes.
The lysis products of either monolayer or suspension cultures were 
centrifuged at 500g at 4°C for 5minutes. The supernatant containing 
cytoplasmic components was discarded, leaving a pellet of nuclei. The pellet 
was resuspended in 20pl Nuclei EZ storage buffer. An aliquot of nuclei was 
set aside for counting with Trypan blue, where the nuclei stain blue due to the 
permeable membranes. The nuclei were stored in aliquots at -80°C.
2.12.2 DNase I digestion
The nuclei were treated with DNase I (Promega) for 10 minutes at 37°C, 
according to the manufacturer's instructions. The reaction was stopped by 
adding Ip l 20mM EGTA pH8.0. The nuclei were kept on ice before and after 
DNase I digestion.
2.12.3 Preparation of genomic DNA from nuciei
Genomic DNA was extracted from DNase I digested nuclei using the DNeasy 
blood and tissue kit (Qiagen), according to the manufacturer’s instructions.
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Briefly, the nuclei were lysed by proteinase K digestion prior to immobilization 
of the DNA to a membrane filter. After washing, DNA was eluted from the 
membrane and quantitated using a NanoDrop spectrophotometer (NanoDrop 
Technologies).
2.12.4 CHART-PCR assay design
A 650bp annotated sequence of the proximal IL-6 promoter is shown in 
Figure 2.2. PCR primers for three regions of the IL-6 promoter (Figures 2.2 
and 2.3) were designed using Primer3 (Rozen and Skaletsky, 2000), a web- 
based application (http://primer3.sourceforqe.net/) (Table 2.6). Primers were 
designed to amplify each of the regions in red (1, 2 or 3) and to quantitate the 
chromatin accessibility in each region of the IL-6 promoter.
Quantitative CHART-PCR was carried out using the QuantiTect Sybr Green 
PCR kit (Qiagen) according to the manufacturer’s instructions. The cycling 
parameters for Region 1 were as follows : 95*C for 15 minutes, 95°C for 30 
seconds followed by 64°C for 30 seconds for 40 cycles. The cycling 
parameters for Region 2 and 3 were : 95°C for 15 minutes, 95°C for 30 
seconds followed by 58°C for 30 seconds for 40 cycles. A melt curve of the 
QPCR product was produced for each reaction to show the specificity of the 
reaction.
2.13. T7 Endonuclease I digestion
Nuclei were digested with T7 Endonuclease I (New England Biolabs), a 
cruciform structure resolving enzyme, for 30 minutes at 37°C, according to
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the manufacturer’s instructions. Genomic DNA was extracted from T7 
Endonuclease I digested nuclei using the DNeasy blood and tissue kit 
(Qiagen), according to the manufacturer’s instructions. Quantitative PCR 
was carried out as described in section 2.12.4.
■gaagaaagtg gcagaagcca 
CHART_5 9 7_5 7 2_F0R 
cctggagacg ccttgaagta
cgcggtggca aaaaggagtc 
REGION 1^ -597 
actgcacgaa atttgaggBt
acacactcca
A /G
ggccaggcag
ttctacaaca
5 7 2  G /C  
gccBctcaca gggagagcca gaacacagaa gaactcagat
gactggtagt attaccttct tcataatccc aggcttgggg ggctgcgatg
C H A R T _ 5 9 7 _
g a g t c a g a g g
5 7 2 _ R E V
aaactcagtt
C H A R T _ 3 7 3
cagaacatct
_FOR REGION 2- 
ttggttttta caaatacaaa
ttaactggaa cgctaaattc tagcctgtta atctggtcac
-373 AnTn
Hcaaaaaac atagctttag cttatttttt ttctctttgt
C H A R T _ 3 7 3 _ R E V
aaaacttcgt gcatgacttc agctttactc tttgtcaaga catgccaaag
tgctgagtca
gcttcttagc
ctaataaaag
gctagcctca
aaaaaaagaa
C H A R T _ 1 7 4 _
atgacgacct
agtaaaggaa gagtggttct 
FOR REGION 3- 
aagctgcact tttcccccta
-174 C/G 
gttgtgtctt gc^atgctaa aggacgtcac attgcacaat cttaataagg
CHART_174_ 
tttccaatea
REV
g c c c c a c c c g ctctggcccc accctcaccc tccaacaaag
atttatcaaa tgtgggattt tcccatgagt ctcaatatta gagtctcaac-
Figure 2.2. Annotated IL-6 promoter sequence
CHART-PCR primers are shown in red. The four common IL-6 promoter 
polymorphisms at position -597, -572, -373 and -174 are hif 
Regions 1, 2 and 3 are indicated (—»).
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Region
GRE NF-IL6
major transcription 
start site
consensus sites GRE GRE translationNE-KB TATA
-557 641 -597 -572 .392 .37^ ' -26 +1 +62 +13
G to A G to C 8AS/12TS
9AS/11TS
lOAs/IOTs
lO A S /IITs
GtoC
Figure 2.3. IL-6 proximal promoter showing CHART-PCR regions 
Schematic representation of the IL-6 promoter showing the polymorphic 
regions in relation to the CHART-PCR regions ( — ) (adapted from Terry et al, 
2000).
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2.14 Atomic Force Microscopy
Atomic force microscopy (AFM) allows the resolution of molecules in the 
nanoscale. Briefly, a cantilever probe scans the surface of the molecule. 
Forces between the molecule and the probe are detected by a laser and 
interpreted as topographical features of the molecule.
2.14.1 Sample preparation
A mica slide (Agar Scientific) was freshly cleaved using Sellotape™. One 
hundred microlitres of dilute (0.001% v/v) 3-Triethoxysilylpropylamine 
(Sigma-Aldrich) was dropped onto the cleaved surface and incubated for 20 
minutes at room temperature, to increase the adsorption of the DNA to the 
mica slide (Umemura et al, 2001). The slide was rinsed three times with 1ml 
MilliQ water and dried with a gentle flow of nitrogen gas.
Five microlitres (2 pg) of supercoiled plasmid DNA was dropped onto the 
prepared mica surface and allowed to adhere for 2 minutes at room 
temperature. The slide was rinsed three times with 1ml MilliQ water and 
dried with a gentle flow of nitrogen gas.
2.14.2 Scanning conditions
DNA molecules were scanned on the atomic force microscope (AFM) (NT- 
MDT) using a cantilever of length 100mm, width 35mm and spring constant 
( k )  5.5 -  22.5 (NSG-10, NT-MDT), where the greater the spring constant, the 
stiffer the cantilever. This affects the scanning properties of the cantilever. 
The natural resonance (frequency) of the cantilever was determined in the
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range of 190 -  325 kHz and was typically between 265 and 268 kHz. The 
magnitude of the peak signal from the cantilever was set within a limit of 20 - 
25 nAmp. The phase angle of the cantilever oscillation was adjusted to 90° 
to the frequency.
DNA molecules adhered to mica slides were visualised by scanning in air in 
tapping mode at 1.56Hz. The images were captured as height (topography) 
or phase (stiffness) files using the NOVA959 software and converted to 
JPEG format.
2.15 Statistical analysis
Statistical significance was set at P<0.05 and P values are quoted to one 
significant figure. One-way analysis of variance (ANOVA) or two-way 
AN OVA with Bonferroni post hoc test, were used to compare values in three 
or more categories. The two-tailed unpaired t test was used to compare 
measurements in two categories. All analysis was done using GraphPad 
Prism version 4.00 for Windows, GraphPad Software fwww.qraphpad.com).
51
Chapter 3 IL-6 gene expression in THP-1 cell line
3.1 THP-1 cells
THP-1 cells were established from the peripheral blood from a 1 year old 
Japanese boy with acute monocytic leukaemia (Tsuchiya et al, 1980). The 
cells are monocytic in morphology and can be differentiated into 
macrophage-like cells using phorbol myristate acetate, a protein kinase C 
activator. The cell stocks used in this work were obtained by Dr Green from 
the Wellcome Trust Centre, Oxford University. The cells were cultured and 
differentiated to macrophage-like cells as described in section 2.7.
3.1.1 Haplotype determination of THP-1 cells
Genomic DNA was extracted from 5 x 10® cultured THP-1 cells in 
suspension, using the DNEasy Tissue kit (Qiagen), according to the 
manufacturer's instructions. Briefly, the cells were lysed to release the 
nucleic acid and treated with proteinase K to remove cellular protein. DNA 
was bound to the spin column membrane, washed and finally eluted into TE 
buffer. DNA concentration (ng/pl) was estimated using the Nanodrop 
spectrophotometer.
The THP-1 IL-6 promoter was genotyped as described in section 2.6.1 and 
the haplotype assigned as -597G / -572C / -37310A10T / -174G written as 
GC10/10G (homozygous), which is rare in a Caucasian population. The 
THP-1 cell line was derived from a Japanese boy and this accounts for the 
rare haplotype.
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3.1.2 Measuring IL-6 mRNA expression in THP-1 cells 
Monocytic (THP-1) (in suspension) and macrophage-like (dTHP-1) 
(adherent) (Figure 3.1) cells at a density of 2.4 x 10® cells per well in a 24 
well tissue culture plate were treated with either 2.5ng/ml IL-1(3, lOOU/ml IFN- 
V or lOOng/ml LPS for 24 hours.
Total RNA was extracted from the cells as described in section 2.10. 
Interleukin-6 mRNA expression was quantitated using the QuantiTect RT- 
PCR Sybr Green kit (Qiagen) according to the manufacturer’s instructions in 
the ABI Prism 7000 (Applied Biosystems) instrument, Interleukin-6 mRNA 
expression was normalized to a MLN51 mRNA expression, a housekeeping 
gene which has been shown not to respond to cytokine stimulation 
(Hamalainen etal, 2001; Khwaja, PhD thesis, Oxford, 2005).
Serial dilutions of total RNA extracted from differentiated THP-1 cells were 
used to produce standard curves for IL-6 and MLN51 mRNA expression 
(Figure 3.2). The log nanogram (ng) amounts of RNA (100,10,10,0.1,0.01) 
were plotted against the cycle threshold (ct) value (mean±SD) and a line of 
best fit derived, giving an equation to calculate amounts of RNA from the 
unknowns.
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Figure 3.1. Phase contrast light microscopy of THP-1 cells
Monocytic (undifferentiated) THP-1 cells were cultured in suspension. 
Macrophage-like (differentiated) THP-1 cells were cultured as an adherent 
monolayer. Magnification x 200 before reproduction.
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&-40.00- y = -1 .5 8 x + 25.471 
R2 = 0.927
-IOtQO-
-0.00-
-2.5 -1.5 -1 -0.5 0 0.5
Log nanogram s (ng)
1.5 2.5
IL-6 standard curve
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R2 = 0.985
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I
-1.5-2.5 2 1 -0.5 0 0.5 1 1.5 2 2.5
Log nanogram s (ng)
MLN51 standard curve
Figure 3.2. Standard curves for IL-6 and WILN51 mRNA expression
Repeated measurements of amplification of serial dilutions of known 
amounts of total RNA are used to produce the standard curves for each 
gene.
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Figure 3.3 is an example of a PCR amplification plot for IL-6 mRNA in 
duplicate samples. The ct value is indicated. This is the cycle number at 
which the amplification becomes exponential, for this sample at 31 cycles of 
the PCR.
Cycle number
Figure 3.3. Amplification plot in duplicate samples, showing cycle 
threshold
RNA was reverse transcribed and amplified in a one step reaction using the 
QuantiTect SYBR Green RT-PCR kit. The graph shows the real time 
amplification plot for IL-6 and the ct value (J,).
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A melt curve or dissociation protocol was performed for all QPCR samples to 
confirm that a specific product was produced during amplification. 
Temperature in the wells was increased from 60°C to 95°C. Specific 
products dissociated at higher temperatures. An example of a specific 
product that dissociates at 80°C is shown in Figure 3.4.
0.6
0.3
Temperature (degrees Celsius)
Figure 3.4. Dissociation plot of IL-6 mRNA in duplicate samples
The dissociation plot is the derivative of the melt curve raw fluorescence data 
as calculated by the ABI Prism 7000 software. Sample shown from duplicate 
wells.
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Although the RNA samples were treated with DNase I prior to QPCR to 
remove DNA contamination, any remaining DNA in the samples could have 
affected the quantitation of mRNA expression. Serial dilutions (1:1, 1:2, 1:4, 
1:8) of total RNA were reverse transcribed and amplified in a one step 
reaction using the QuantiTect SYBR Green RT-PCR kit. Amplification of the 
sample with the greatest amount of RNA appeared first at cycle 24 as 
expected. The sample with the least RNA appeared last after 28 cycles 
Figure 3.5).
10
8c8
i{
o0:m
Ï5
-5
in i
in 2
1 in4
......1 in 8
Cycle number
Figure 3.5. Amplification plots of serial dilutions of RNA
The graph shows the real time amplification plot for IL-6 in one sample of 
RNA.
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3.2 IL-6 mRNA expression in THP-1 ceils
3.2.1 Induction of IL-6 mRNA expression in macrophage-like THP-1 cells 
treated for 24 hours
The THP-1 monocyte-macrophage cell line was assessed as a model of 
inflammation by differentiating monocytic cells into macrophage-like cells and 
challenging them with known inflammatory stimuli. The level of IL-6 mRNA 
expression was quantitated as a marker of inflammation.
THP-1 cells were differentiated into macrophage-like cells and induced to 
express IL-6 mRNA (Table 3.1) when treated with IFN-y (P<0.001) and LPS 
(P<0.05). There was a small though non significant induction of IL-6 with IL-
1(3.
IL-6/MLN61
mRNA
expression
Control IL-lp IFN-Y LPS
MeantSD
n=3 3.1 ±0.43 4.0+0.035 6.6±0.70*** 4.7±0.36*
Table 3.1 Induction of IL-6 mRNA expression in macrophage-like THP-1 
cells treated for 24 hours
Macrophage-like THP-1 cells were stimulated for 24 hours and IL-6 mRNA 
expression quantitated by QPCR. *** P<0.001, * P<0,05
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3.2.2 induction of IL-6 mRNA expression in monocytic and macrophage­
like THP-1 cells treated for 24 hours
IL-6 mRNA expression was quantitated in undifferentiated monocytic THP-1 
cells and macrophage-like THP-1 cells to assess the difference in IL-6 mRNA 
expression between the cell types (Figure 3.6). Stimulation of macrophage­
like THP-1 cells with interferon-y resulted in a significant increase in IL-6 
mRNA expression (P<0.001), compared to monocytic THP-1 cells. There 
was no significant difference in IL-6 expression between monocytic and 
macrophage-like THP-1 cells at baseline or when stimulated with IL-1|3 or 
LPS.
***
10.0
Control ILI-p IFN-y 
Treatment
LPS
THP-1
dTHP-1
Figure 3.6. Induction of IL-6 mRNA expression in monocytic and 
macrophage-like THP-1 cells treated for 24 hours
Monocytic and macrophage-like THP-1 cells were stimulated for 24 hours 
and IL-6 mRNA expression quantitated by RT-QPCR. Mean±SD, n=3. *** 
P<0.001
60
3.2.3 Dose response of THP-1 cells to Interferon-y
The induction of IL-6 mRNA expression by IFN-y in macrophage-like THP-1 
cells was further tested by comparing lOOU/ml with ten times this dose at 2 
and 24 hours of treatment (Figure 3.7). A ten fold increase in the dose of 
IFN-y resulted in a significant four fold difference in IL-6 mRNA expression 
after 24 hours of treatment (P<0.001). There was no significant difference in 
the IL-6 mRNA expression at 2 hours of treatment with both lOOU/ml and 
lOOOU/ml.
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Figure 3.7. Fold change in IL-6 mRNA expression in macrophage-like 
THP-1 cells treated for 2 and 24 hours with lOOU/ml and 1000U/ml IFN-y
Macrophage-like THP-1 cells were treated with IFN-y and IL-6 mRNA 
expression quantitated by QPCR. Mean±SD, n=3. *** P<0.001
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3.3 Inhibition of iL~6 mRNA expression in THP-1 ceiis
The effect of two commonly prescribed statins was investigated on the 
endogenous and inducible IL-6 mRNA expression in the macrophage-like 
differentiated THP-1 cell line. Although the statin experiments were also 
done using IL-1p as the inflammatory challenge, no IL-6 gene expression 
was induced as described earlier. As LPS is a broad stimulus of IL-6 in 
macrophages, it was decided to stimulate the macrophage-like THP-1 cells 
with IFN-y.
3.3.1 Effect of statins on endogenous IL-6 mRNA expression
Macrophage-like THP-1 cells were treated with either atorvastatin or 
pravastatin for 24 hours to assess the effect of statins on IL-6 mRNA 
expression in vitro (Figure 3.8). There was no significant difference in the 
level of IL-6 mRNA expression when treated with an increasing dose of either 
atorvastatin or pravastatin for 24 hours.
3.3.2 Effect of statins on IL-6 mRNA expression in macrophage­
like THP-1 cells stimulated with iFN-y
When macrophage-like THP-1 cells were stimulated with IFN-y and treated 
with an increasing dose of statin for 24 hours, there was a significant dose- 
dependent response in the inhibition of IL-6 mRNA expression with 
atorvastatin (P=0.01) and with pravastatin (P=0.02) (Figure 3.9).
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Figure 3.8. Fold change in IL-6 mRNA expression in unstimulated 
macrophage-like THP-1 cells treated with an increasing dose of statin
There was no significant difference in IL-6 mRNA expression quantitated by 
QPCR in macrophage-like THP-1 cells were treated with an increasing dose 
of atorvastatin (P=0.8) or pravastatin (P=0.6) (ANOVA) for 24 hours. 
Mean±SD, n=8.
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Figure 3.9. IL-6 mRNA expression in IFN-y stimulated macrophage-like 
THP-1 cells treated with an increasing dose of statin
Cells were treated with 10OU/ml interferon-y and an increasing dose of statin 
for 24 hours and IL-6 mRNA expression quantitated by QPCR. MeaniSD, 
n=8. ***P=0.01, *P=0.02 (ANOVA).
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3.4 IL-6 gene expression in THP-1 ceiis
Monocytic and macrophage-like THP-1 cells were stimulated as before with 
IL-lp , IFN-y or LPS for 16 hours to assess the IL-6 mRNA and protein 
expression in these cells, to compare the IL-6 gene expression between 
monocytic and macrophage-like cells. The shorter time of stimulation was 
chosen to allow comparison with transient transfection data of HA Khwaja 
(PhD thesis, Oxford, 2005).
3.4.1 IL-6 mRNA expression in THP-1 cells stimulated for 16 hours
The level of IL-6 mRNA expression was assessed after 16 hours of 
stimulation with IL-1p, IFN-y or LPS in monocytic and macrophage-like THP- 
1 cells (Figure 3.10). There was no significant difference between monocytic 
and macrophage-like THP-1 cells at baseline or stimulated with IL-1p or IFN- 
y for 16 hours. There was a significant difference (P<0.05) between the two 
cell types when stimulated for 16 hours with LPS. Overall, there was less IL- 
6 mRNA induction at 16 hours of stimulation when compared with the 
induction at 24 hours of stimulation. This suggests that there is a differential 
IL-6 mRNA response that is dependent on time and stimulus.
3.4.2 Measuring IL-6 protein concentration in cell culture supernatants
A composite standard curve was prepared from five different assays run in 
duplicate. The standard curve is shown in Figure 3.11. The pg/ml values of 
IL-6 protein expression were calculated from the spline of the fit of the 
standard curve.
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Figure 3.10. IL-6 mRNA expression in monocytic and macrophage-like 
cells stimulated for 16 hours
Monocytic and macrophage-like THP-1 cells were stimulated for 16 hours 
and the levels of IL-6 mRNA expression quantitated by QPCR. Mean±SD, 
n=3. * P<0.05
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Figure 3.11. Composite standard curve of IL-6 protein concentration
Serial dilutions of the IL-6 standard were used to produce the standard curve. 
The curve is a composite of five experiments (mean±8D), with each standard 
assayed in duplicate.
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3.4.3 IL-6 protein expression in THP-1 cells stimulated for 16 hours
IL-6 protein expression was measured in cell supernatants from monocytic 
and macrophage-like THP-1 cells stimulated as described in section 3.1.2 for 
16 hours (Figure 3.12). IL-6 protein expression was measured using a 
validated high sensitivity chemiluminescence ELISA (R&D Systems). There 
was a significant difference between the monocytic and macrophage-like 
cells when stimulated with LPS (P<0.001) for 16 hours. This was consistent 
with the LPS-induced IL-6 mRNA expression at 16 hours and with previous 
reports of LPS-induced IL-6 production in THP-1 cells (Suda et al, 1999).
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Figure 3.12. IL-6 protein expression in THP-1 cells stimulated for 16 
hours
The left and right axes in this chart show the difference in measured IL-6 
protein in cell culture supernatants between macrophage-like THP-1 (dTHP- 
1) and monocytic (THP-1) cells respectively. MeaniSD, n=3, *** P<0.001.
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3.5. Conclusions
There was a significant induction of IL-6 mRNA in macrophage-like THP-1 
cells differentiated with PMA and stimulated with IFN-y for 24 hours or LPS 
for 16 hours, whereas monocytic THP-1 cells expressed very low levels of IL- 
6 mRNA upon stimulation. There was a significant increase in the LPS- 
induced IL-6 protein expression in macrophage-like THP-1 cells, which was 
consistent with the increased IL-6 mRNA expression observed at 16 hours 
with LPS stimulation, and this time- and stimulus-dependent response of IL-6 
gene expression is consistent with previous reports that the IL-6 gene is 
differentially activated.
Macrophage-like THP-1 cells activated by IFN-y responded to statin 
treatment by down-regulating IL-6 mRNA expression and this could indicate 
a role for statins at the level of the atherosclerotic plaque by reducing local 
inflammation and having a potential effect on plaque stability. There was no 
quantitative difference in the overall effect of the two drugs, which suggests a 
possible class effect. These data provide an insight into the mechanisms of 
action of statins and provide further evidence for their beneficial anti­
inflammatory effects.
Quantitation of IL-6 gene expression was validated in the THP-1 monocyte- 
macrophage cell line model of inflammation. In the next chapter, a primary- 
monocyte-derived macrophage model is developed to assess the role of IL-6 
promoter haplotype on IL-6 gene expression.
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Chapter 4 IL-6 expression in primary monocyte-derived 
macrophages
4.1 Ex vivo cuiture of monocyte-derived macrophages 
Peripheral blood mononuclear cells from nine individuals (n=3 individuals 
possessing the high-responder GG9/11G allele, n=3 individuals 
heterozygous for the low-responder AG8/12C allele, and n=3 individuals 
homozygous for the AG8/12C allele) of known IL-6 proximal promoter 
haplotype (Table 4.1) were prepared on a density gradient from whole blood 
using Histopaque-1077, according to the manufacturer’s instructions. The 
haplotype frequencies (AG8/12C (0.35), GG10/11G (0.30), GG10/10G (0.18) 
and GG9/11G (0.17)) were consistent with the reported values (Terry et al, 
2000).
Table 4.1 Haplotype assignment for volunteers recruited to the study 
(over page)
Volunteers are indexed 1-27 and IL-6 proximal promoter polymorphisms are 
indicated across the top of the table. Possession of the allele is indicated by 
X. Highlighted individuals were recalled for culture of primary monocyte- 
derived macrophages. Complete genotyping results are shown in Appendix 
III.
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The yield of peripheral blood mononuclear cells (1.19x10®/ml whole blood ± 
0.44, mean±SD) was determined following Histopaque-1077 centrifugation 
and found to be within the normal range (lymphocytes 1.5 -  4 x 10®/ml, 
monocytes 0.2 -  0.95 x 10®/ml). Mononuclear cells were cultured as 
described in 2.11.1 and 2.11.2. The percentage (meantSD) adherence 
(14.14 ± 5.28) and viability (95.16 ± 3.02) of monocyte-derived macrophages 
was determined at 8 days of primary culture, prior to stimulation.
Monocyte-derived macrophages were stimulated using interleukin-1 (3 
interferon gamma or LPS, according to Table 2.5. After stimulation, the cell 
culture supernatants were removed and stored at -80°C for ELISA analysis of 
cytokine production. RNA was extracted from the adherent cells for QPCR 
and in some cases, intact, functional nuclei were extracted for CHART-PCR.
4.2 IL-6 mRNA expression in primary monocyte-derived macrophages
The method for RNA extraction and optimization of the QPCR assay was 
described in sections 2 and 3 respectively.
A published assay of chitotriosidase mRNA expression (a biochemical 
marker of macrophage activation, associated with lysosomal diseases and an 
early response to infections including malaria) in monocyte-derived 
macrophages from healthy volunteers was used as a positive control to 
demonstrate that the method for preparing monocyte-derived macrophages 
and assaying mRNA expression could reproduce reported results 
(Malaguarnera of al, 2005). In contrast to the methods presented here the
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authors enriched the monocyte population by using CD14 magnetic beads 
prior to differentiation, used the housekeeping gene GAPDH and calculated 
the fold change using the ct values instead of a standard curve. Primary 
monocyte-derived macrophages from healthy volunteers were stimulated 
with 100U/ml IFN-y for 2, 4 and 24 hours. Although there were differences 
between the methods, the fold change over unstimulated control was similar 
to the published data (Figure 4.1).
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Figure 4.1. Chitotriosidase mRNA expression in monocyte-derived 
macrophages
Monocyte-derived macrophages were stimulated for 2, 4 and 24 hours and 
chitotriosidase and MLN51 mRNA expression determined by QPCR. The 
graph shows the fold change over unstimulated chitotriosidase expression 
(mean±SD) of triplicate cell culture wells, assayed in duplicate. *P<0.05.
The primary monocyte-derived macrophage model was validated further by 
measuring the IL-6 mRNA expression in differentiating monocyte-
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macrophages, as well by comparing the inter- and intra- individual 
differences in IL-6 mRNA expression.
4.2.1 IL-6 expression in unstimulated differentiating monocyte-derived 
macrophages
Total RNA was extracted from differentiating monocyte-macrophages at 48 
hours, 96 hours and 192 hours after seeding out. QPCR was carried out as 
described previously. Cells in the first 48 hours of ex vivo primary culture 
showed increased IL-6 expression relative to the housekeeping gene MLN51. 
There was a significant reduction in IL-6 mRNA expression (P=0.01) over 
time from 48 hours to 192 hours (8 days). The level of IL-6/MLN51 
expression dropped to basal level (P=0.004). There was a small though non 
significant decrease in the level of MLN51 mRNA expression (P=0.09) 
(Figure 4.2 and Table 4.2).
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Figure 4.2. Baseline IL-6 and MLN51 mRNA expression in differentiating 
monocyte-derived macrophages
IL-6 and MLN51 mRNA expression was measured in differentiating 
monocyte-macrophages from three individuals. The graph shows the mean 
of the three experiments in triplicate cell culture wells, assayed in duplicate 
(mean±SEM). *P=0.01 for IL-6, **P=0.004 for IL-6/MLN51.
Hours IL-6* MLNSI"^ IL-6/MLN51**
48 3.85±0.55 1.40±0.05 2.99±0.26
96 0.83±0.28 0.99+0.23 0.83±0.14
192 0.19±0.08 0.60±0.14 0.31±0.06
Table 4.2. Baseline IL-6 and MLN51 mRNA expression in differentiating 
monocyte-derived macrophages
Measured QPCR values (ng) of IL-6 and MLN51 expression and IL-6 
normalized to MLN51 in differentiating monocyte-macrophages. *P=0.01, 
**P=0.004.
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4.2.2 Inter-individual IL-6 mRNA expression in unstimulated primary 
monocyte-derived macrophages
RNA was extracted from monocyte-derived macrophages at 8 days + 0, 8, 
24, 48 hours of ex vivo culture. The levels of IL-6 and MLN51 mRNA 
expression were measured by QPCR (Figure 4.3). There was little variability 
observed at each time point between the individuals.
Baseline IL-6 mRNA expression increased at 24 and 48 hours following 
differentiation, whilst there was little Increase from 0 hours in the mean IL-6 
expression in the group at 8 hours. There was a significant difference 
between 8 and 24 hours (P=0.04). Only one individual was cultured to 48 
hours due to the limited number of cells available.
In further experiments stimulation with 1L-1P, IFN-y or LPS was carried out 
for 8 hours where the maximum induction in IL-6 expression could be 
observed.
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Figure 4.3. lL-6 mRNA expression in unstimulated monocyte-derived 
macrophages over time
The graph shows the IL-6 mRNA expression normalized to MLN51 in each 
individual (•) over time in ex vivo culture following differentiation (not all 
individuals were measured at all time points). The cells were not stimulated 
and the points show baseline IL-6 mRNA expression. MeantSD is given for 
each time point.
The data at 8 hours were analysed to ascertain whether sex or age affect IL- 
6 mRNA expression. There was no significant difference between the 
unstimulated IL-6 mRNA expression in men and women (P=0.3) (Figure 4.4) 
and there was no significant difference between the unstimulated IL-6 mRNA 
expression in the 25-40 year or 41-60 year age groups (P=0.9) (Figure 4.5).
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Figure 4.4. Effect of sex on baseline IL-6 mRNA expression in 
monocyte-derived macrophages
The graph shows the IL-6 mRNA expression normalized to MLN51 in each 
individual. The cells were not stimulated and the points show baseline IL-6 
mRNA expression
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Figure 4.5. Effect of age on baseline IL-6 mRNA expression in 
monocyte-derived macrophages
The graph shows the IL-6 mRNA expression normalized to MLN51 in each 
individual. The cells were not stimulated and the points show baseline IL-6 
mRNA expression.
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4.3 IL-6 mRNA expression in stimulated primary monocyte-derived 
macrophages
4.3.1 Intra-individual IL-6 mRNA expression in stimulated primary 
monocyte-derived macrophages
It has already been shown that there was little variation in IL-6 mRNA 
expression between individuals at baseline (section 4.2.2). IL-6 mRNA 
expression in stimulated monocyte-derived macrophages was studied in one 
individual in three separate experiments (blood was taken on three different 
occasions over one year) to determine the intra-individual variability of the 
model (Figure 4.6).
The results show that there was little intra-individual variability when 
stimulated with IL-ip or IFN-y. There was some variability in the LPS- 
induced IL-6 mRNA response although this was not significant.
A time-course of IL-ip stimulation in monocyte-derived macrophages from 
one individual showed that IL-6 mRNA appeared to peak between 4 and 24 
hours of stimulation, whilst the housekeeping gene (MLN51) mRNA 
expression remained constant with stimulation at 2 (P<0.001), 4 (P<0.001) 
and 24 hours (P<0.01) (Figure 4.7).
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Figure 4.6. Intra-individual fold change in IL-6 mRNA expression in 
stimulated monocyte-derived macrophages
Monocyte-derived macrophages were stimulated for 8 hours. Induced intra­
individual IL-6 mRNA expression was normalized to MLN51 from three 
separate experiments over one year.
*** *** **
2.5n
2.0-
O)
«  1.0- IL-6
0.5-
lA—MLN510.0 2 4 24
Hours
Figure 4.7. IL-6 and MLN51 mRNA expression in IL-ip stimulated 
primary monocyte-derived macrophages
Monocyte-derived macrophages were stimulated for 2, 4 and 24 hours and 
IL-6 and MLN51 mRNA expression determined by QPCR. MeantSD of 
triplicate cell culture wells, assayed in duplicate. ***P<0.001, **P<0.01.
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4.3.2 IL-6 mRNA expression in stimulated primary monocyte- 
derived macrophages
Nine individuals were recalled for the functional assay as described in section 
4.1. Monocyte-derived macrophages were stimulated for 8 hours. IL-6 
mRNA expression relative to MLN51 was measured by QPCR (Figure 4.8). 
There was a significant difference between the LPS- and IL-1P- (P<0.05) and 
IFN-y-(P<0.05) induced IL-6 response.
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Figure 4.8. Induction of IL-6 mRNA expression in stimulated monocyte- 
derived macrophages
The graph shows the fold induction over unstimulated IL-6 mRNA 
expression.
n=9, mean±SEM, *P<0.05.
A small study of three individuals was undertaken to look at the effect of 
priming monocyte-derived macrophages with IFN-y on IL-6 mRNA
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expression prior to adding LPS to the cell culture medium. There was no 
difference in the mean IL-6 mRNA expression between LPS alone (4.8 -  
454) and when primed with IFN-y for 12 (16 -  308) and 24 hours (2.5 ~ 295), 
but there was an increase compared to IFN-y alone (0.54 -  4.8) (Figure 4.9).
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Figure 4.9. IL-6 mRNA expression in IFN-y primed monocyte-derived 
macrophages
The graph shows the fold induction of IL-6 mRNA expression in individuals 
stimulated with IFN-y alone, LPS alone and IFN-y plus LPS.
4.3.3 IL-6 mRNA expression in stimulated monocyte-derived 
macrophages by haplotype
IL-6 mRNA expression was analysed by IL-6 SNP haplotype to investigate 
whether previous transient transfection analysis of haplotype-specific IL-6
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promoter:reporter-gene constructs is consistent with the situation in ex wVo 
stimulated monocyte-derived macrophages. The previous findings were:
1. Reporter gene expression assays in the ECV304 cell line demonstrated 
that the IL-6 promoter GG9/11G haplotype showed higher IL-6 
transcriptional induction by IL-1(3 (Terry etal, 2000).
2. IL-6 promoter-reporter constructs transfected into the human 
microvascular endothelial cell line (HMEC-1) respond to inflammatory 
stimuli in a haplotype-dependent manner; the highest transcriptional 
induction by !L-1|3 was associated with the GG9/11G and GC10/10G 
haplotypes and the lowest induction with AG8/12C and AG8/12G 
haplotypes (P<0.001) (Khwaja, PhD thesis, Oxford 2005; Khwaja, Terry, 
Green, manuscript submitted).
3. Quantitative RT-PCR analysis of the IL-6 mRNA from 60 carotid plaques 
taken at the time of carotid endarterectomy showed that the GG9/11G 
haplotype was the only haplotype associated with increased IL-6 mRNA 
in the plaque (P=0.005) (Khwaja, PhD thesis, Oxford 2005; Khwaja, 
Terry, Green, manuscript submitted).
IL-1P-, IFN-y- and LPS-induced IL-6 mRNA expression were analysed in 
terms of haplotype (Figures 4.9, 4.10, 4.11). The group of individuals was 
assigned as possessing one or two copies of the GG9/11G allele 
(+GG9/11G) or none (-GG9/11G). There was a highly significant difference 
(P=0.0004) in the IL-ip-induced IL-6 mRNA response between the haplotype
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groups. This was consistent with previous findings that the inducible IL-6 
response in individuals with the +GG9/11G haplotype is greater than those 
with -GG9/11G haplotype (Figure 4.10). Although the mean of the 
+GG9/11G group (3.4) was greater than that of the -GG9/11G (1.3), this 
failed to reach statistical significance difference (P=0.06) in the IFN-y- 
induced IL-6 mRNA response between the haplotype groups (Figure 4.11). 
The LPS-induced IL-6 response showed no significant difference between 
the haplotype groups (P=0.5) (Figure 4.12). LPS induces a strong 
inflammatory response and these results suggest that the mechanism of LPS 
action on IL-6 mRNA expression is not solely mediated through the IL-6 
promoter.
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Figure 4.10. IL-6 mRNA expression in IL-1p stimulated monocyte- 
derived macrophages by haplotype
The graph shows the fold induction of IL-6 mRNA expression following 
stimulation with IL-1(3 for 8 hours. ***P=0.0004.
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Figure 4.11. IL-6 mRNA expression in IFN-y stimulated monocyte- 
derived macrophages by haplotype
The graph shows the fold induction of IL-6 mRNA expression following 
stimulation with IFN-y for 8 hours (P=0.06).
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Figure 4.12. IL-6 mRNA expression in LPS stimulated monocyte-derived 
macrophages by haplotype
The graph shows the fold induction of IL-6 mRNA expression following 
stimulation with LPS for 8 hours (P=0.5).
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4.4 !L-6 protein expression in human piasma and primary celi cuiture 
supernatants
4.4.1 IL-6 protein in human plasma
Plasma samples were collected from each individual recruited to the project. 
IL-6 protein levels were measured in twenty-five out of twenty-seven 
individuals to assess the plasma IL-6 expression in normal, healthy 
individuals. The IL-6 protein concentration in stored plasma samples was 
1.3±0.48 pg/ml (mean±SD), which was within reported values for IL-6 in 
circulating plasma (Endler et al, 2004; Cardellini et ai, 2007; Zalewska et al, 
2006). One individual was observed at 3.0pg/ml which was still within the 
reported range. (Figure 4.13a).
These results were analysed to determine the effect of sex, age and 
haplotype on IL-6 plasma concentration (Figures 4.13b-d). There was no 
significant sex difference in plasma IL-6 (male 1.22±0.22, female 1.3±0.6) 
(Figure 4.13b). The volunteers recruited to this study were aged 25 to 60 
years. The age range was split into two groups of roughly equal size for the 
analysis, 25-40 years (n=11, 1.2+0.39) and 41-60 years (n=14, 1.3±0.58). 
There was no significant difference in plasma IL-6 between the two groups 
(Figure 4.13c). The IL-6 promoter haplotype was assigned for each 
individual as possessing one or two copies of the GG9/11G allele 
(+GG9/11G) or none (-GG9/11G) (Figure 4.13d). There was no significant 
difference in plasma IL-6 concentration between the two defined haplotype 
groups (+GG9/11G 1.1 ±0.29, -GG9/11G 1.3+0.55).
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4.4.2 IL-6 protein concentration in ex vivo cell culture supernatants
IL-6 protein was measured in supernatants from unstimulated monocyte- 
derived macrophages at 8 days of ex vivo culture + 2 ,8  and 24 hours (Figure 
4.14). There was no significant difference in the baseline IL-6 protein 
expression at 2 (2.6±1.2pg/ml, mean±SEM), 8 (10±3.8pg/ml) and 24 
(8.3±2.2pg/ml) hours.
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Figure 4.14. IL-6 protein concentration in cell culture supernatants from 
unstimulated monocyte-derived macrophages
Basal IL-6 protein was measured in cell culture supernatants. Each 
individual value is the mean of the assay duplicates for the individual from 
triplicate cell culture wells.
IL-6 protein concentration was measured in primary cell culture supernatants 
collected after stimulation at 2, 8 and 24 hours (Figure 4.15). The peak IL-6 
protein values were measured at 8 hours. IL-ip stimulated cells produced a 
significant increase in IL-6 (P=0.002) and there was an especially strong
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response to LPS (P=0.02). The LPS response was damped down by 24 
hours, indicating that the IL-6 protein response is short-lived and this is 
consistent with its role as an early response gene. No significant difference 
in IL-6 supernatant concentration was observed at 2 or 24 hours of 
stimulation.
The data from the 8 hour supernatant collection were analysed by haplotype 
(Figures 4.16). Although there was no significant difference in IL-6 
concentration between +GG9/11G and -GG9/11G individuals in the 
supernatants from stimulated cells, the +GG9/11G group showed a 
consistently greater concentration than the -GG9/11G group. There was a 
significant difference between the haplotype groups at baseline (P=0.04), 
suggesting a possible haplotype-specific effect on IL-6 production in non­
activated monocyte-derived macrophages.
Figure 4.16. IL-6 protein concentration in supernatants from primary 
monocyte-derived macrophages 
(over page)
The graphs show the individual IL-6 protein expression in monocyte-derived 
macrophages at baseline and when stimulated for 8 hours with IL-ip, IFN-y 
and LPS. Each individual value is the mean of the assay duplicates for the 
individual from triplicate cell culture wells. *P=0.04.
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There was no significant difference between the haplotype groups at 2 or 24 
hours when stimulated with IL-1p, IFN-y or LPS, although the number of 
individuals in these groups was small (n=4 and n=3 respectively).
A short time-course of IL-6 protein expression in IL-ip stimulated monocyte- 
derived macrophages was performed in two individuals (Figure 4.17), one 
from each haplotype group, to determine if the IL-6 concentration at 8 hours 
of stimulation was due to an accumulation of IL-6 over time in the cell culture 
supernatants. The values at 0.25 and 0.5 hours in +GG9/11G and 0.25 
hours in -GG9/11G were below the detection limit of the assay. No 
significant difference was observed in the time points at 1 and 2 hours, 
however, there was a significant difference between the two individuals at 8 
hours (P<0.001). This finding was not consistent with the lack of haplotype- 
specific IL-6 protein expression in the haplotype analysis of all individuals 
(Figure 4.16), and therefore cannot be confirmed as a haplotype-specific 
difference. Furthermore, a time-dependent IL-6 response was observed with 
increasing IL-6 concentration the longer the stimulation time with IL-1(3.
Given the highly significant haplotype-specific IL-6 mRNA expression with IL- 
ip  stimulation it would suggest that a similar response might be observed at 
the protein level. This was not the case, however, and could be due to a 
longer half-life in the cell culture environment than in vivo. These data do 
suggest that the IL-6 protein could be accumulating in the supernatant and 
this may account for the lack of haplotype-specific response.
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Figure 4.17. lL-6 protein concentration in supernatants from monocyte- 
derived macrophages stimulated with IL-ip over a short time-course
The graph shows the IL-6 concentration (mean±SD) for an individual of each 
haplotype from triplicate cell culture wells, assayed in duplicate. ***P<0.001.
4.5 Conclusions
IL-6 mRNA was inducible in a primary monocyte-derived macrophage model, 
with low inter- and intra- individual variability. It was demonstrated that cells 
derived from individuals of either +GG9/11G or -GG9/11G haplotype varied 
little In their IL-6 mRNA expression at baseline. However, when these cells 
were exposed to IL-ip, IL-6 mRNA was induced in an IL-6 promoter 
haplotype-specific manner, with IL-6 mRNA expression in cells from 
+GG9/11G individuals more Induced than -GG9/11G Individuals and this is 
consistent with previous reports (Terry et al, 2000; Khwaja, PhD thesis, 
Oxford 2005; Khwaja, Terry, Green, manuscript submitted).
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IL-6 protein concentration peaked after 8 hours of stimulation. All individuals 
were responsive to inflammatory challenge regardless of IL-6 promoter 
haplotype, which is an important positive control for this model. That is, all 
individuals were able to mount an inflammatory challenge at the protein level 
in spite of low mRNA expression levels. Stimulated and unstimulated 
monocyte-derived macrophages from +GG9/11G individuals produced more 
IL-6 protein ex vivo than -GG9/11G individuals, although this was not 
significant in stimulated cells.
A key inflammatory marker such as IL-6 requires fine control in vivo and it 
could therefore be a dysregulation of this fine control that accounts for the 
effects of IL-6 in inflammatory conditions, including atherosclerosis, 
inflammatory bowel disease and arthritis. One possible mechanism of 
haplotype-specific IL-6 mRNA expression is investigated in the next chapter.
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Chapter 5 Chromatin remodelling in the IL-6 promoter 
5. 1 /L-6 promoter chromatin accessibility in THP-1 ceils
In order to investigate a possible mechanism of action of IL-6 gene activation, 
the Chromatin Accessibility Real Time Quantitative PGR (CHART-PCR) 
assay was adapted (Brettingham-Moore et al, 2005) and validated in THP-1 
cells. In this assay, whole, functional nuclei were extracted from the 
macrophage-like THP-1 cells and subjected to DNase I digestion. Chromatin 
is described as open (euchromatin) or closed (heterochromatin) depending 
on the state of gene activation, that is, open chromatin is an indication of 
transcriptional activity (Kuhnert et al, 1992). Open, active chromatin is more 
readily digested by DNase I than closed, inactive chromatin, thus the greater 
the digestion, the more open and active is the area of chromatin and the less 
PCR product is formed in the CHART-PCR assay.
5.1.1 Design of CHART-PCR assay
Three sets of primers were designed to span the proximal IL-6 promoter. 
The regions were named 1,2 or 3, where region 1 contains the -597 A/G and 
-572 G/C SNPs, region 2 covers the -373 AnTn polymorphism and region 3 
contains the -174 C/G SNP. Quantitative PCR was performed using the 
QuantiTect PCR Sybr Green kit on the ABI Prism 7000 (Applied Biosystems).
A standard curve was prepared for each region using serial dilutions of 
genomic DNA.
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5.1.2 Optimisation of CHART-PCR assay
In monocytic and macrophage-like THP-1 cells at baseline, nuclei were 
extracted and treated with DNase I for 5, 10 and 15 minutes at 37°C to 
determine the optimum time of digestion with DNase I to leave quantifiable 
PCR fragments. The products of this DNase I digestion were subjected to 
electrophoresis on a 2% (w/v) agarose gel in IX  TBE buffer (Figure 5.1). An 
equal amount of template DNA (20ng) was added to each PCR reaction and 
equal amounts were loaded onto the gel. The product at 10 minutes was 
clearly greater (that is, less digested) than those at 5 and 15 minutes.
163bp
1 2 3 4 5 6 7
Figure 5.1. Agarose gel electrophoresis of PCR products of DNase I- 
digested nuclei
The figure shows the PCR products of IL-6 promoter region 1 digested for 5, 
10 and 15 minutes from nuclei of macrophage-like (2-4) and monocytic (5-7) 
THP-1 cells. (1) DNA 50kb ladder.
The QPCR results of this one experiment are represented in Figure 5.2. In 
each case the chromatin from the macrophage-like cells was more open than
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the monocytic cells after 10 minutes of DNase I digestion and less PCR 
product was formed. The quantitative results confirmed the gel 
electrophoresis data.
All subsequent DNase I digestions were performed at 37°C for 10 minutes.
Figure 5.3 compares the endogenous DNase and exogenous DNase I 
digestion of nuclei from monocytic and macrophage-like THP-1 cells in region 
1 of the IL-6 promoter. These data showed that chromatin in the IL-6 
promoter region 1 was more open in the macrophage-like cells than in the 
monocytic cells at baseline and this was consistent with the results observed 
in Figure 5.2. More PCR product was measured in the nuclei from both the 
monocytic and macrophage-like THP-1 cells not treated with DNase I than 
the DNase l-treated nuclei (P<0.001). The amount of PCR product measured 
in nuclei from monocytic THP-1 cells not treated with DNase I was 
significantly greater than that measured in the macrophage-like cells 
(P<0.001).
The QPCR DNase I digestion values were normalized to the undigested 
values for all further analyses, to account for potential differences in PCR 
amplification.
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Figure 5.3. IL-6 promoter region 1 chromatin accessibility at baseline in 
THP-1 cells
Quantitative PCR result (n=3, meanlSD) from IL-6 promoter region 1 in nuclei 
from monocytic and macrophage-like cells treated at 37°C for 10 minutes 
with or without DNase I. ***P<0.001.
5.1.3 Chromatin accessibility in IL-6 promoter in THP-1 cells 
THP-1 cells were cultured as monocytes or differentiated into macrophage­
like cells as previously described. The cells were stimulated with IL-1(3, IFN- 
V and LPS for 16 hours. Nuclei were extracted as described in section 2.12.1 
and DNase I digested at 37°C for 10 minutes.
CHART-PCR was carried out as described in section 2.12.4 in three regions 
of the proximal IL-6 promoter and the results are shown in Figure 5.4.
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In each region, the chromatin from macrophage-like cells was more open 
than the chromatin in monocytic cells (that is, less PCR product). In region 1 
(P<0.01) and region 3 (P<0.001), there was a significant difference in the 
chromatin response to IL-1(3. In addition, there was a significant difference in 
the chromatin between monocytic and macrophage-like cells in the control 
(unstimulated) samples (P<0.01), which was consistent with the baseline 
CHART-QPGR results in monocytic and macrophage-like cells in Figure 5.2.
To summarise the above data and to draw a comparison between monocytic 
and macrophage-like THP-1 cells. Figure 5.5 shows the chromatin 
accessibility profile from baseline and with stimulation for each cell type in all 
IL-6 promoter regions. No significant difference in the chromatin profile was 
observed between the regions of the IL-6 promoter. Overall, chromatin 
accessibility in the IL-6 promoter in nuclei from the monocytic cells was 
shown to be less open than that from macrophage-like cells. This was 
consistent with mRNA levels, where IL-6 induction was greater in 
macrophage-like cells than in monocytic cells. Chromatin was less 
accessible and therefore less active when the cells were stimulated with IL- 
ip  compared to stimulation with IFN-y and LPS in both monocytic and 
macrophages-like THP-1 cells and this finding was consistent with the IL-6 
mRNA expression levels shown in Figure 3.10.
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Figure 5.5. Chromatin accessibility in the IL-6 promoter in THP-1 cells
The graphs show the profile of chromatin remodelling across three regions of 
the IL-6 promoter in monocytic and macrophage-like THP-1 cells. The PCR 
products were normalized to the undigested PCR value (n=3, meaniSD). 
The points are joined to emphasise the dynamic response of each region of 
the IL-6 promoter to stimulation.
5.2 Chromatin accessibility in the IL-6 promoter in primary monocyte- 
derived macrophages
One possible mechanism of action for the differential IL-6 gene expression 
observed could be the state of the chromatin in the IL-6 promoter. As shown 
in the THP-1 model, chromatin accessibility was related to IL-6 gene 
expression, and the latter was therefore measured in the nuclei from primary 
cells.
5.2.1 Chromatin remodelling in the IL-6 promoter at 2 and 8 hours of 
stimulation
Four individuals (n=2 from each haplotype group) were re-called for this part 
of the study. Monocyte-derived macrophages were stimulated for 2 and 8
1 0 0
hours in the usual way and nuclei were extracted as described in section 
2.12.1. The percentage nuclei yield from four individuals was 21.25+10.11 % 
(meanlSD). All CHART-PCR assays were performed in duplicate on nuclei 
from triplicate cell culture wells for each individual.
Figure 5.6 shows the dynamic response of the IL-6 proximal promoter 
chromatin to stimulation over time. There were differences in the profiles of 
stimulation across the regions and between 2 and 8 hours of stimulation. 
The chromatin in the control (unstimulated) samples in Region 2 at 2 and 8 
hours was more accessible than in the other regions. This was consistent 
with the finding in macrophage-like THP-1 cells where the unstimulated 
chromatin in Region 2 was similarly more accessible than Regions 1 and 3 
(Figure 5.4).
Chromatin in nuclei from monocyte-derived macrophages stimulated with IL- 
ip  showed decreasing accessibility from Region 1 to 2 to 3 at 2 hours of 
stimulation. At 8 hours of stimulation with IL-ip there was a small increase in 
chromatin accessibility in Region 1 when compared to control. Chromatin 
accessibility decreased in Regions 2 and 3.
Stimulation of monocyte-derived macrophages with IFN-y resulted in a small 
increase in chromatin accessibility in Region 1 at 2 hours which was further 
opened at 8 hours, when compared to the control. Chromatin was less 
accessible in Region 2 at 2 hours compared with 8 hours of stimulation with
101
IFN-y. Chromatin accessibility increased in Region 3 compared to Region 2 
at 2 hours, but was less accessible in Region 3 than in Region 2 at 8 hours. 
Stimulation of monocyte-macrophages with LPS for 2 hours showed that 
chromatin was less open in Region 1 and Region 3 than Region 2. By 8 
hours of stimulation chromatin was similarly more open in Region 2 than 
Region 1, whilst the chromatin in Region 3 was dramatically more open, 
compared with Region 3 at 2 hours. This finding was consistent with the IL-6 
gene expression data where LPS-stimulated monocyte-derived macrophages 
showed a significant increase in both mRNA and protein, compared to IL-ip 
and IFN-y.
The changes in chromatin accessibility were however very small compared to 
the gene expression, suggesting a contribution to the fine regulation of IL-6 
expression.
Figure 5.6. Chromatin accessibility in IL-6 promoter in nuclei from 
monocyte-derived macrophages stimulated for 2 and 8 hours 
(over page)
The graphs show the chromatin accessibility across the three regions of the 
IL-6 promoter at baseline, stimulated for 2 hours and 8 hours with IL-ip, IFN- 
y or LPS. The values are the mean±8EM of 4 individual experiments, where 
the DNase I digested QPCR values were normalized to the undigested 
QPCR values.
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The fold change in chromatin accessibility at 8 hours was calculated (the 
change in chromatin accessibility with stimulation over control) and this was 
found to be significantly different between region 1 and region 2 at 8 hours of 
IL-ip stimulation (P<0.05). Region 2 was less accessible to DNase I 
digestion than region 1 and 3 when stimulated with IL-ip and INF-y, but not 
with LPS stimulation (Figure 5.7). All three regions were accessible to 
DNase I digestion in the LPS stimulated cells, suggesting a possible 
mechanism for the greater inducibility of IL-6 with LPS stimulation.
Region 1 
RegionZ 
Regions
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Treatment
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Figure 5.7. Fold change In chromatin accessibility in the IL-6 promoter 
at 8 hours of stimulation
The graph shows the fold change in chromatin accessibility across the three 
regions of the IL-6 promoter stimulated for 8 hours with IL-ip, IFN-y or LPS. 
The values are the meanlSEM of 4 individual experiments. *P<0.05.
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5.2.2 Haplotype-specific IL-6 promoter chromatin accessibility
There were haplotype-specific differences In chromatin accessibility at both 2 
and 8 hours of stimulation with IL-1P, IFN-y or LPS (Figure 5.8). These were 
not statistically significant, most likely due to the small number of individuals 
studied (n=2 for each IL-6 promoter haplotype +GG9/11G and -GG9/11G).
Chromatin from the +GG9/11G group was clearly more accessible than the 
-GG9/11G group in region 3 at 2 hours when stimulated with LPS and at 8 
hours at baseline and when stimulated.
There was little stimulus or haplotype variability in region 1, although at 8 
hours of stimulation chromatin accessibility was greater in both groups of IL-6 
promoter haplotype.
In region 2 the chromatin was more accessible in the -GG9/11G haplotype 
group, at baseline and with stimulation with IL-1p and IFN-y but not with LPS, 
where the +GG9/11G group was more accessible at 8 hours.
Figure 5.8. Haplotype-specific chromatin accessibility in IL-6 promoter 
(over page)
The graphs show the haplotype-specific chromatin accessibility across the 
three regions of the IL-6 promoter at baseline, stimulated for 2 hours and 8 
hours with IL-1p, IFN-y or LPS. The values are the mean±SEM of 4 
individual experiments (n=2 for each IL-6 promoter haplotype +GG9/11G and 
-GG9/11G), where the DNase I digested QPCR values were normalized to 
the undigested QPCR values.
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5.2.2 Chromatin remodelling in the IL-6 promoter over a short time- 
course of IL-ip stimulation
A shorter time-course of IL-ip stimulation showed that there were time- and 
region- specific significant differences in chromatin accessibility in one 
+GG9/11G and one -GG9/11G individual (Figure 5.9).
In region 1 chromatin from the +GG9/11G individual was more open than that 
from the -GG9/11G individual from 0.25 hours to 8 hours (P<0.001).
In region 2, chromatin from the +GG9/11G individual was more open from 
0.5 hours to 2 hours and showed a significant decrease in chromatin 
accessibility at 8 hours of stimulation with IL-1p, when compared to the -  
GG9/11G individual (P<0.001).
In region 3, chromatin from the +GG9/11G individual was more accessible to 
DNase I digestion in the early time-course but became less open by 2 hours 
of stimulation and equal to that in the -GG9/11G individual.
In all three regions, the chromatin from the +GG9/11G individual was more 
accessible to DNase I digestion than chromatin from the -GG9/11G 
individual, that is the chromatin was more open and therefore active, apart 
from at 8 hours in region 2 where the chromatin from the +GG9/11G 
individual became less accessible to DNase I digestion. In region 3 at 2 and 
8 hours the chromatin accessibility was similar between the two individuals of 
different IL-6 promoter haplotype.
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These short time-course data were amalgamated with the 2 and 8 hour data 
from all individuals (n=4) to produce a composite graph of chromatin 
remodelling in the IL-6 promoter in nuclei from IL-1(3 stimulated monocyte- 
derived macrophages (Figure 5.10). These data demonstrated chromatin 
remodelling within 0.5 hours of stimulation in the three regions of the IL-6 
proximal promoter. There was a significant difference in the chromatin 
accessibility at 8 hours between region 1 and region 2 (P<0.05); that is, 
region 2 was less accessible to DNase I digestion. A similar though not 
significant effect was observed with IFN-y but not LPS stimulation at 8 hours 
(as shown in Figure 5.7).
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Figure 5.10. Chromatin remodelling in the IL-6 promoter
The graph shows the fold change in chromatin accessibility (mean±SEM) in 
region 1, region 2 and region 3 of the IL-6 promoter, in nuclei from monocyte- 
derived macrophages stimulated with IL-1(3 over a short time-course (n=2 
0.25 to 1 hour, n=4 2 to 8 hours from triplicate cell culture wells, assayed in 
duplicate). *P<0.05.
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5.3 DNase I hypersensitivity in the /L»6 promoter
Using CHART-PCR allows a more sensitive quantitation of DNase I 
hypersensitivity than the traditional DNase I foot printing method (McArthur et 
al, 2001). It was observed that the CHART-PCR absolute values 
(nanograms of PCR product) from region 2 were lower than those from 
region 1 or region 3 in nuclei extracted from unstimulated primary monocyte- 
derived macrophages (Figure 5.11). The ratios of region 1:2 and region 3:2 
were 22+10 and 17+7.2 (mean±SEM) respectively.
Ë 1.5
Regioni Region2 Regions 
IL-6 prom oter region
Figure 5.11. Quantitative PCR product from IL-6 promoter regions 
Each region of the IL-6 promoter was quantitated by CHART-PCR in four 
individuals (mean±SEM) following DNase I digestion in nuclei from 
unstimulated monocyte-derived macrophages. *P=0.02.
This result was also seen in QPCR of genomic DNA extracted from white 
blood cells and not DNase I digested. The input template amount was equal, 
the reaction efficiency of each QPCR reaction was similar (Region 1 68.9%, 
Region 2 68.4%, Region 3 78.4%), the PCR product was specific as
1 1 0
determined by melt curve analysis and gel electrophoresis (no additional 
product was formed) and no difference was observed on gel electrophoresis 
compared to Region 1 and Region 3 (although this is not strictly quantitative). 
The PCR primers were checked by BLAST2 (Altschul et al, 1997) for 
sequence alignment within region 2 of the IL-6 promoter 
(http://zeon.well.ox.ac.uk/blast2/).
This low amplification of region 2 seems to be the result of an effective lack 
of template. This may be due to DNA secondary structure in region 2 that 
makes it less available as template in the QuantiTect Sybr Green QPCR 
system, as agents used In PCR such as DMSG to aid the Taq polymerase 
through secondary structure cannot be added to the quantitative Sybr Green 
QPCR reaction.
In chromatin from unstimulated primary monocyte-derived macrophages, 
DNase l-digested CHART-PCR values from each IL-6 proximal promoter 
region were normalized to the corresponding undigested values (to account 
for differences in PCR amplification) and the ratio of region 1:2 and 3:2 
showed a two- to three-fold difference respectively. The ratio (mean±SEM) 
of region 1:2 (3.3±1.2) and region 3:2 (2.0+0.73) showed that there was 
increased digestion with DNase I in the IL-6 promoter region 2, compared to 
region 1 and region 3, that is that the chromatin in region 2 was more 
accessible to DNase I, suggesting that this region is a DNase I 
hypersensitive site and could be constitutively open in these cells.
I l l
5.4 Conclusions
The THP-1 cell line was found to be a useful model for studying the 
differences between monocytic and macrophage-like cells in a model lL-6 
response to acute inflammation. The data from the THP-1 cell line work 
provide proof of principle for the primary monocyte-derived macrophage work 
to follow. Chromatin accessibility in macrophage-like THP-1 cells was 
greater than in monocytic cells and this was consistent with IL-6 gene 
expression levels in macrophage-like cells being greater than in monocytic 
cells. The chromatin from IL-1(3 stimulated THP-1 cells was less accessible 
to DNase I digestion, that is the chromatin was less active, which was 
consistent with the low IL-6 gene expression level in response to IL-1(3.
In primary cells, there was a variable response across the IL-6 promoter such 
that each region of the IL-6 promoter was more or less accessible to DNase I 
digestion depending on stimulation with either IL-1(3, IFN-y or LPS for 2 or 8 
hours. This could contribute to the difference in the IL-6 mRNA response to 
each stimulus. IL-6 promoter chromatin remodelling occurred within 30 
minutes of stimulation with IL-1(3, with the chromatin in the IL-6 promoter 
from the +GG9/11G individual more accessible than that from the -GG9/11G 
individual, suggesting a haplotype-specific response.
Although the measured effect of chromatin remodelling in the IL-6 proximal 
promoter was small when cells were treated with an inflammatory stimulus, 
the data does suggest that dynamic chromatin remodelling occurs across the 
IL-6 promoter and is consistent with the differential activation of IL-6.
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Furthermore, the data showing that the IL-6 promoter region 2 in chromatin 
from unstimulated THP-1 macrophage-like cells and primary monocyte- 
derived macrophages was more accessible to DNase I digestion suggested 
that this region could include a DNase I hypersensitive site. As DNase I 
hypersensitivity has been shown to occur in regions of secondary structure 
including cruciforms (Ward etal, 1991), stem-loops or branches, the following 
chapter looks at secondary structure in the IL-6 promoter.
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Chapter 6 Secondary structure in the IL-6 promoter
6.1 Cruciform structure in the iL-6 promoter
T7 Endonuclease I resolves DNA cruciform structures and Holliday junctions 
in a structure-dependent manner (Birkenbihl and Kemper, 1998) and was 
used to identify this secondary structure in the IL-6 promoter in intact nuclei 
isolated as described in section 2.12.1.
6.1.1 Validating the T7 Endonuclease I assay
The T7 Endonuclease I enzyme was supplied with a positive control 
(pUC(ATg)) to assess reaction conditions. pUCCATg) is derived from the 
pUC19 plasmid with nine AT doublets inserted between the EcoRI site and 
PstI site. This sequence will form a cruciform structure.
One unit of enzyme converted > 90% of 1 pg of supercoiled cruciform 
pUC(ATg) to > 90% linear form in 10 minutes at 37°C (Figure 6.1). 
Quantitative PCR of digested pUC(ATg) using M l3 universal primers 
confirmed the gel electrophoresis results (Figure 6.2). There was a 
significant difference between the percentage undigested and the percentage 
digested at 10, 30 and 60 minutes. The products of the QPCR reactions are 
also shown in Figure 6.1.
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Figure 6.1. Agarose gel electrophoresis of pUC(ATg) digested with T7 
Endonuclease I
pUC(ATg) plasmid DNA was digested with T7 Endonuclease I at 37°C for 10, 
30 and 60 minutes. 1. Supercoiled DNA ladder, 2. Undigested supercoiled 
plasmid pUC(ATg), approximately 2.7kb, 3. pUC(ATg) digested for 10 
minutes, 4. pUC(ATg) digested for 30 minutes, 5. pUC(ATg) digested for 60 
minutes, 6. DNA Ikb ladder, 7-10. QPCR product of 2-5, 11. DNA 50bp 
ladder.
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Undigested 10 30
Digestion (minutes)
Figure 6.2 . Percentage digestion of pUG(ATe) with T7 Endonuclease I
pUC(ATg) plasmid DNA was digested with T7 Endonuclease I at 37°C for 10, 
30 and 60 minutes and quantitated using QPCR. n=3, mean±SD. 
***p<0 001.
6.1.2 Cruciform structure in IL-6 promoter haplotype constructs 
Constructs of the IL-6 promoter haplotypes were previously prepared in the 
pGL3 basic plasmid (Terry et al, 2000; Khwaja, PhD thesis, Oxford 2005; 
Khwaja, Terry, Green, manuscript submitted). The plasmids with AG8/12C 
and GG9/11G constructs were subjected to electrophoresis in a 1% (w/v) 
agarose gel to assess the level of supercoiled plasmid DNA (Figure 6.3) prior 
to digestion with T7 Endonuclease I and atomic force microscopy. There 
was a high degree of supercoiled DNA in both plasmid preparations. 
Supercoiled DNA is required for cruciform formation (Mikheikin etal, 2006).
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Figure 6.3. Supercoiled plasmid DNA containing construct of IL-6 
promoter haplotype AG8/12C and GG9/11G
Agarose gel electrophoresis of supercoiled pGL3 basic plasmid with (2) 
AG8/12C construct and (3) GG9/11G construct. There was a high degree of 
supercoiled plasmid DNA (<—) at approximately 5.4kb (the theoretical size of 
the plasmid plus insert). (1) Supercoiled DNA ladder 10kb.
5kb
?
Figure 6.4. T7 Endonuclease I digestion of pGL3 plasmid DNA with IL-6 
promoter construct AG8/12C
Plasmid pGL3 with IL-6 promoter construct was digested with T7 
Endonuclease I at 37°C for 10, 30 and 60 minutes. 1. Supercoiled DNA 
ladder, 2. Undigested supercoiled construct, 3. Construct digested for 10 
minutes, 4. Construct digested for 30 minutes, 5. Construct digested for 60 
minutes. Linearised plasmid (<—).
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One microgram of supercoiled pGL3 basic plasmid containing the AG8/12C 
IL-6 promoter construct was digested with 1 unit of T7 Endonuclease I for 10, 
30 and 60 minutes. The gel electrophoresis of this digestion is shown in 
Figure 6.4. There was a time-dependent increase in a single linear fragment 
produced from the plasmid digestion.
The percentage template remaining after digestion was quantitated by QPCR 
in region 1 and region 2 of the IL-6 promoter (Figure 6.5 and Table 6.1). 
There was a significant reduction in the amount of template available for 
QPCR in both region 1 and region 2 of the IL-6 promoter (P<0.001), 
indicating that both regions of the IL-6 promoter were affected by digestion of 
cruciform structure.
100-1
D) 75-
i  I  50
E 25-
0 10 30 60
Digestion (minutes)
Region 1
100-1
gi 75-
s l 504
-LuaËHBpamiga
30
Digestion (minutes)
10 60
Region 2
Figure 6.5. Quantitative PCR of IL-6 promoter construct AG8/12C 
following 17 Endonuclease I
QPCR of IL-6 promoter region 1 and region 2 in supercoiled pGL3 plasmid 
with IL-6 promoter construct AG8/12C following digestion with T7 
Endonuclease I for 10, 30 and 60 minutes at 37°C. Each experiment was in 
triplicate, assayed in duplicate. ***P<0.001.
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Both region 1 and region 2 showed significant digestion with T7 
Endonuclease 1 with no measurable template remaining in region 2 after 60 
minutes digestion (Table 6.1), although region 2 was significantly more 
digested than region 1 at 10 minutes of digestion (P<0.001).
T7 Endonuclease 1 digestion (minutes)
10 30 60
Region 1 
(% meaniSD) 4.4+0.66*** 3.9+0.61 0.96±0.82
Region 2 
(% meaniSD) 0.56±0.95 2.2+0.35 ND
Table 6.1. Percentage template remaining following T7 Endonuclease I 
digestion in region 1 and region 2 of IL-6 promoter
QPCR of IL-6 promoter region 1 and region 2 in supercoiled pGL3 plasmid 
with IL-6 promoter construct AG8/12C following digestion with T7 
Endonuclease I for 10, 30 and 60 minutes at 37‘"C. Each experiment was in 
triplicate, assayed in duplicate. ***P<0.001, ND not detectable.
6.2 Cruciform structure in the /L-6 promoter in functional nuclei from 
primary monocyte-derived macrophages
Secondary structure and protein-DNA complexes are preserved in functional 
nuclei. Nuclei from unstimulated and IL-1(3 stimulated monocyte-derived 
macrophages from four individuals were digested with T7 Endonuclease I for 
30 minutes at 37°C .
119
Quantitative PCR of the remaining template showed that all regions of the IL- 
6 promoter were digested and that there was no significant difference in 
digestion between the regions, although region 2 was more digested than 
region 1 and region 3, suggesting more secondary structure in region 2 
(Figure 6.6). Although there was no significant difference between T7 
Endonuclease I digestion in nuclei from unstimulated and IL-1|3 stimulated 
monocyte-derived macrophages, there was less digestion when stimulated,. 
This suggests less secondary structure in stimulated conditions, perhaps 
allowing access for transcription factor binding.
100-1
7 .5±3.8
Regioni Region2 Regions 
IL-6 promoter regions
Unstimulated monocyte-derived macrophages
100-1
o> 75-
§ » 50-
25-
28±11 17+11 30±13
Regioni Region2 Regions 
IL-6 promoter regions
IL-ip stimulated monocyte-derived macrophages
Figure 6.6. 17 Endonuclease I digestion of IL-6 promoter in nuclei from 
primary monocyte-derived macrophages
Nuclei from unstimulated and IL-1p stimulated monocyte-derived 
macrophages were digested with T7 Endonuclease I and quantitated using 
QPCR. The results are the mean±SEM of four individuals, from triplicate cell 
culture wells and assayed in duplicate. The values given are the percentage 
template remaining after digestion in each region (mean±SEM).
The observation that all regions were strongly digested with T7 
Endonuclease I was unexpected and suggests that either the T7
12 0
Endonuclease I reaction is not specific or that cruciform structures are 
present, but may not be confined to region 2 of the IL-6 promoter.
To test the possibility that the T7 Endonuclease I reaction was not specific for 
promoter secondary structure, a non-promoter region in intron 3 of the IL-6 
gene was compared to the IL-6 promoter (Figure 6.7). The graphs show very 
clearly that in unstimulated and IL-1(3 stimulated monocyte-derived 
macrophages the intron 3 region is dramatically less digested than the IL-6 
promoter regions 1, 2 and 3.
100i lOOl
»  75- g  76-1 =^ E ^a « 50- a « 504
E 25- - r -  E 25-
Regionl Region2 Regions IntronS Regioni Region2 Regions IntronS
IL-6 CHART-PCR region IL-6 CHART-PCR region
Unstlmulated monocyte-derived macrophages IL-ip stimulated monocyte-derived macrophages
Figure 6.7.17 Endonuclease I digestion of IL-6 promoter and IL-6 intron 
3 in nuclei from monocyte-derived macrophages
Nuclei from unstimulated and IL-ip stimulated monocyte-derived 
macrophages were digested with T7 Endonuclease I and quantitated using 
QPCR. The results are the mean±SEM of four individuals, from triplicate cell 
culture wells and assayed in duplicate. ***P<0.001.
There was no significant difference in T7 Endonuclease I digestion in the IL-6 
promoter regions between the IL-6 promoter haplotype +GG9/11G and -  
GG9/11G (data not shown).
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6.3 DNA structure and folding predictions
The proximal IL-6 promoter sequence (650bp) (given in section 2.12.4 Figure 
2.1) was entered into a web-based DNA folding prediction program to assess 
the predicted secondary structure. The sequence for two IL-6 promoter 
haplotypes (AG8/12C and GG9/11G) as well as the THP-1 haplotype 
sequence was entered into MFOLD (Zuker, 2003; Mathews et al, 1999; 
SantaLucia, Jr., 1998) (http://www.bioinfo.roi.edu/applications/mfold/). It was 
assumed that the DNA is linear for the purposes of this prediction. The 
default reaction conditions were set at 37°C and 1M Na\
The results of the folding predictions are given as AG (kcal/mol) (Gibbs free 
energy change). This is the energy required to initiate a spontaneous 
chemical reaction. A negative AG value denotes a spontaneous reaction. 
The greater the -AG, the greater the driving force behind the reaction and 
the most energetically favourable (Table 6.2).
There was a small difference in the AG between AG8/12C and GG9/11G. 
The THP-1 AG was marginally more energetically favourable than the 
GG9/11G and AG8/12C. To analyse the difference between AG8/12C and 
GG9/11G IL-6 promoter haplotype, the AG8/12C haplotype sequence was 
changed by one base at a time (Table 6.2). By changing the -597 A to G, the 
AG approached that predicted for GG9/11G, and by changing the -174 C to 
G the AG matched that predicted for the GG9/11G (AG=-68.67).
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Figures 6.8 represents the most energetically favourable folding prediction for 
each sequence and shows the overall difference between the AG8/12C and 
GG9/11G haplotypes and the THP-1 haplotype. No difference was seen in 
the AnTn region. The major difference occurred around the -597 SNP with a 
smaller difference at -174. Detailed annotated views of the AG8/12C and 
GG9/11G folded sequences are included in Appendix II. By changing the - 
597 A to G the folding profile changed to resemble that of the GG9/11G 
profile, and by changing the -174 C to G the profile matched that predicted 
for the GG9/11G.
This suggests that the -373 AnTn polymorphism alone does not contribute to 
the difference in the folding predictions observed.
Figure 6.8. Folding profiles of IL-6 promoter haplotype sequence 
(over page)
The figures represent the lowest energy folding prediction for each IL-6 
promoter sequence (AG8/12C -66.57 kcal/mol, GG9/11G -68.67 kcal/mol, 
THP-1 GC10/10G -69.69 kcal/mol, GG8/12C -68.35 kcal/mol. GG8/12G - 
68.67 kcal/mol). These predictions were derived from the MFOLD web- 
software by entering the sequence variants.
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6.4 Atom ic force microscopy o f DNA cruciform structure 
Secondary structure in supercoiled plasmid DNA was visualised using Atomic 
Force Microscopy (AFM). Further to the biochemical experiments with T7 
Endonuclease I which demonstrated the presence of cruciform structure or 
structures in the IL-6 promoter, AFM was used to visually assess the 
secondary structure. In all images, the scale is in micrometres (pm) as 
indicated in the figures. A schematic diagram of cruciform extrusion in 
supercoiled DNA is shown in Figure 6.9.
Figure 6.9. Cruciform structure in supercoiled DNA
AT rich regions are extruded as cruciform structure (—>) under conditions of
negatively supercoiled DNA (adapted from Gellert at al, 1983).
6.4.1 Cruciform structure in pUC(ATg)
pUC(ATg) was shown to be digested by T7 Endonuclease I which resolved 
cruciform structures in DNA. A sample of undigested pUC(ATg) (0.4pg/pl) 
was prepared on freshly cleaved mica treated with 0.001% (v/v) APS. 
Images were scanned in tapping mode at a rate of 1.56Hz. A representative 
series of images is shown with increasing resolution from 10pm x 10pm to 
1pm X  1pm (Figure 6.10). These images showed a dense pack of 
supercoiled DNA plasmid molecules. By increasing the resolution, more 
structures became visible. At a resolution of 0.5pm x 0.5pm a molecule with
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a cruciform shape was observed and this was further resolved at 0.3pm x 
0.3pm and 0.2pm x 0.2pm (Figure 6.11).
The expected length of the relaxed plasmid would be approximately 1pm 
(0.33nm x 2.7kb). The supercoiled molecule visible in the 0.5pm image was 
measured at approximately 250nm in length, one quarter of the length of the 
relaxed molecule. Super coiling was well demonstrated in the 0.3pm image 
(*). Two twists were observed over a length of 50nm. One helical turn of 
DNA is approximately 3.4nm (10.4bp) in length (Wang, 1979), therefore the 
twists seen were not two helical turns but supercoiled twists comprising 
fourteen to fifteen DNA helices.
The small branched region indicated by the arrow could be a cruciform 
structure. It measured 30nm in length across the structure, approximately 
340bp of supercoiled structure, although this could not be verified.
Figure 6.10. Atomic force microscopy images of undigested pUC(ATg) 
(over page)
Undigested pUC(ATg) scanned in tapping mode with increasing resolution 
from 10pm x 10pm to 1 pm x 1 pm.
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The pUC(ATg) positive control sample (0.4pg/pl) was digested with T7 
Endonuclease I to disrupt the cruciform structure. Figure 6.12 is a 
representative series of AFM images of increasing resolution showing linear 
molecules, not densely packed as in the undigested sample. The molecules 
were measured at approximately 1pm in length, which was consistent with 
the expected length for the pUC(ATg) (2.7kb).
At high resolution, it was observed that the secondary structure had been 
resolved by T7 Endonuclease I digestion and the molecules became more 
linear with no apparent supercoiled or secondary structure. These images 
were consistent with the biochemical data (Figure 6.13).
Figure 6.12. Atomic force microscopy images of T7 Endonuclease I 
digested pUCfATg)
(over page)
Digested pUC(ATg) scanned in tapping mode with increasing resolution from 
10pm X  10pm to 1 pm X  1pm.
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6.4.2 Cruciform structure in IL-6 promoter haplotype constructs
A sample of supercoiled plasmid DNA with IL-6 promoter construct GG9/11G 
(0.5pg/pl) was prepared on freshly cleaved mica treated with 0.001% (v/v) 
APS. Images were scanned in tapping mode at a rate of 1.56Hz (Figure 
6.14). The images demonstrate the increasing resolution of the supercoiled 
plasmid with the IL-6 promoter construct GG9/11G. The supercoiled 
structure of the plasmid was visible as a dense white area (->) and a 
branched or cruciform region (*) was observed in the AFM images
In the 0.5pm image the molecule was measured at approximately 500nm. 
The relaxed plasmid would be expected to be approximately 2pm in length 
(5.4kb). The supercoiled molecule was therefore a quarter of the relaxed 
molecule.
A sample of supercoiled plasmid with the IL-6 promoter AG8/12C promoter 
construct (0.5pg/pl) was prepared for AFM as described. A representative 
series of images is shown in Figure 6.15. The branched regions were 
measured at approximately 30nm to 40nm which was consistent with the 
measurements in the pUC(AT9) samples.
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6.5 Conclusions
The specificity of T7 Endonuclease I for cruciform DNA structure was not 
shown in this thesis, however it is an accepted method for determining 
cruciform topology (Mizuuchi, 1982; Panayotatos and Fontaine, 1987). An 
appropriate negative control to demonstrate the specificity of the reaction to 
the ATg insert, and not to another sequence within the plasmid, would be to 
digest the native pUC19 vector with T7 Endonuclease I under the same 
conditions. T7 Endonuclease I was shown to cleave the supercoiled 
pUC(ATg) and putative cruciform structure was demonstrated in the IL-6 
promoter in constructs and in intact nuclei from primary monocyte-derived 
macrophages.
T7 Endonuclease I digestion of the IL-6 promoter was shown to differ from 
the digestion of a non-promoter region, which suggests a promoter-specific 
cleavage of secondary structure. No haplotype difference was observed in 
the T7 Endonuclease I digestion in nuclei prepared from monocyte- 
macrophages. The non-significant Increase in template remaining after T7 
Endonuclease I digestion in nuclei from IL-ip stimulated monocyte-derived 
macrophages suggests a biological significance which could be due to 
individual variability or could be the result of a dynamic process which the 
promoter undergoes in conditions of stimulation, as the promoter becomes 
more accessible to transcription factor binding and active transcription.
DNA folding predictions suggest a haplotype-specific profile. Although the 
predicted folding patterns did not show specific cruciform structure, it did
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predict a high degree of secondary structure, branches and stem loops. The 
limitations of the default reaction conditions suggest that a different profile 
could be expected under supercoiled conditions or where chromatin is under 
torsional stress by nucleosomes, for example. This analysis requires more 
sophisticated software and processing than was available here.
Although the AFM results were qualitative, it was clear that DNA secondary 
structure could be visualised and quantitated. Measurements were made 
and this provided an understanding of the topography of supercoiled plasmid 
DNA. Achieving high resolution requires clean sample preparation and 
storage, constant temperature and low relative humidity. The spring 
constant, or hardness, of the tapping cantilever was also a contributing 
factor. DNA is a soft biological material with a strong negative charge. The 
cantilever needs to tap across the topography of the DNA recognising the 
height and contrast of the sample. In conditions of high static or high relative 
humidity, it was more difficult to obtain high resolution images.
Cruciform and branched secondary structures were visible in both the 
AG8/12C and GG9/11G IL-6 promoter haplotype constructs but no 
quantifiable difference was observed between the haplotypes.
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Chapter 7 Discussion
7.1 THP-1 cell line : a monocyte-macrophage model o f the IL-6 
inflammatory response
Macrophage-like THP-1 cells have been shown to be similar to primary 
monocyte-derived macrophages with 0.88 correlation in cytokine gene 
expression profiles (Kohro et al, 2004). The IL-6 response was determined 
as a marker of inflammation in differentiated and undifferentiated THP-1 
cells.
Monocytic THP-1 cells were differentiated into macrophage-like cells using 
the phorbol ester PMA. PMA has been shown to activate the protein kinase 
C pathway of mitogen activated protein kinase (MAP) and extracellular signal 
related kinase (ERK) in differentiating HL-60 cells to macrophages (Schultz 
et al, 1997) and ERK in the Jurkat T cell line (Bradshaw et al, 1996). 
However, in THP-1 cells it has been shown to activate the ERK and c-Jun 
kinase but not the p38 MAP kinase (Carter et al, 2001).
There was little IL-lp-induced IL-6 gene expression in both the monocytic 
and macrophage-like THP-1 cells and the chromatin accessibility data (a 
measure of active transcription) showed that the IL-6 proximal promoter 
chromatin was less active when the cells were stimulated for 16 hours with 
IL-ip than at baseline or when stimulated with IFN-y or LPS. Low expression 
of IL-6 was also observed in PMA-differentiated THP-1 cells as part of a 
study of human intestinal epithelial and smooth muscle cells (Ng et al, 2003). 
Interleukin-6 protein levels were not detectable in response to IL-1p
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stimulation for 24 hours. This may not be due to lower receptor number as 
PMA appears to induce the IL-1r in THP-1 cells (Spriggs et al, 1990).
In early reports, it was proposed that treating THP-1 monocytic cells with 
lOOnM PMA for 48 hours resulted in increased llL-1 receptor antagonist (IL- 
Ira) an anti-inflammatory cytokine, which decreased IL-1p binding 
(Bienkowski et al, 1990). It was later shown that soluble IL-Ira was 
degraded more slowly in monocytic THP-1 cells treated with LPS, suggesting 
a role in the down-regulation of the pro-inflammatory cytokine IL-1p (Learn et 
al, 2000). Although the THP-1 cells in this study were not endotoxin tolerant 
(pre-treated with LPS), upregulation of IL-Ira in PMA differentiated THP-1 
cells could explain the low response of THP-1 cells to IL-ip.
Cells of the monocyte-lineage including THP-1, U937 and primary 
monocytes, have been shown to constitutively express NF-kB 
(Frankenberger et al, 1994). Interleukin-1 p signals through the interleukin-1 
receptor associated kinase leading to the induction of signalling pathways 
including p38 MAP kinase and the activation of NF-kB. The action of IL-Ira 
is independent of the signalling pathway for IL-ip, that is there is no effect on 
the components of the signalling pathway (Evans et al, 2006). The inhibition 
of the IL-ip response was shown to be ATP dependent and cell specific. 
The experiments were performed in transfected HUVEC and HeLa cells and 
as macrophages are not easy to transfect it may not be possible to confirm 
this, however it does suggest a possible mechanism for the macrophage-like 
THP-1 response.
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stimulation of THP-1 cells for 16 hours with IFN-y or LPS did not result in a 
significant difference in IL-6 promoter chromatin accessibility between 
monocytic and macrophage-like THP-1 cells but there was overall more 
chromatin accessibility in the IL-6 promoter in the macrophage-like cells. 
However, at 16 hours of stimulation with LPS, there was a significant 
difference in IL-6 gene expression in monocytic and macrophage-like THP-1 
cells. At 24 hours of treatment with IFN-y, there was a significant difference 
in IL-6 mRNA expression between monocytic and macrophage-like THP-1 
cells. Thus, macrophage-like THP-1 cells responded as expected to IFN-y 
and LPS stimulation. The THP-1 protein data were consistent with previous 
reports for IFN-y and LPS stimulation (Biondillo etal, 1994).
Macrophages play a central role in the development of atherosclerosis, an 
inflammatory process, and are found in atherosclerotic plaques. Statins are 
used clinically for lipid-lowering but their pleiotropic effects, including an anti­
inflammatory role, are being increasingly reported. Interleukin-6 mRNA 
expression was inhibited by statins in macrophage-like THP-1 cells. 
Atorvastatin and pravastatin are prescribed clinically to lower cholesterol by 
inhibiting endogenous cholesterol synthesis. The therapeutic dose of 
atorvastatin calcium is 10-80mg daily whilst the dose for pravastatin sodium 
is 10-40mg daily. This was calculated as 4-16pM and 6-23pM respectively. 
The concentrations of the statins used in vitro were IpM, 5pM and 20pM, 
thus the in vitro concentrations were in line with the physiological therapeutic 
doses in vivo. There was no cytotoxic effect of the statins at higher 
concentrations as the levels of the housekeeping gene MLN51 remained
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constant throughout the experiment. In this study, the statins were prepared 
in DMSO to ensure equivalent entry into the cells. This means that the 
reduction in IL-6 gene expression achieved by the two statins could be 
directly compared.
Although the two statins used in this study have the same mechanism of 
action on cholesterol metabolism, they differ in their chemical structure, 
which affects absorption and metabolism in vivo. Pravastatin is hydrophobic 
and would normally be bound to a carrier molecule for entry into the 
hepatocytes. Atorvastatin is lipophilic and enters the cells by passive 
diffusion through the cell membrane. The elimination half-lives in vivo also 
differ; pravastatin has a half-life of 1-3 hours whilst atorvastatin has a half-life 
of 14 hours (Pan et ai, 1990; Cilla, Jr. et al, 1996).
Despite atorvastatin being approximately four times as potent as pravastatin 
with respect to LDL-cholesterol lowering (Pincus, 1998), no significant 
difference between pravastatin and atorvastatin on the reduction of IFN-y 
stimulated IL-6 mRNA expression was observed in vitro. There was no 
observed affect of the statins on unstimulated IL-6 mRNA expression, which 
suggests that the mechanism of action could be through statin-induced 
repressors of IL-6 transcription.
Atorvastatin has been shown to act as a repressor of MHC-II mediated T cell 
activation only when stimulated with IFN-y (Fehr et al, 2004). Treatment with 
atorvastatin has been shown to decrease the activation of the transcription
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factor NF-kB, possibly by inhibiting protein isoprenylation, in primary rat 
vascular smooth muscle cells and in the U937 monocyte cell line in vitro 
(Ortego et al, 1999) and in human endothelial cells and vascular smooth 
muscle cells in vitro (DichtI et al, 2003). This is consistent with the findings in 
primary adipocytes treated with cerivastatin (Van Harmelen etal, 2003).
In a study of primary adipocytes cultured from rabbits fed a high cholesterol 
diet and treated with atorvastatin for two weeks, interleukin-6 levels were 
measured by ELISA in cell culture supernatants. Atorvastatin resulted in 
decreased IL-6 concentration in a dose dependent manner up to lOpM (Zhao 
and Zhang, 2003). Simvastatin inhibited TNFa-induced IL-6 and IL-8 
production in fibroblast-like cells from patients with rheumatoid arthritis 
(Yokota et al, 2006).
Treatment with pravastatin in in vivo clinical trials showed a reduction in 
cardiovascular events and a reduction in circulating levels of the cytokines 
TNF-a, IL-6 and IL-8 (Rosenson et al, 1999). The PROVE-IT Study and 
REVERSAL Trial (Salam, 2004) showed a reduction in CRP levels in patients 
prescribed either atorvastatin or pravastatin. Data from the Myocardial 
Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study 
Investigators (Schwartz et al, 2001) produced evidence of the effect of 80mg 
daily atorvastatin on plasma C-reactive protein, serum amyloid A and IL-6 in 
patients enrolled in this study (Kinlay et al, 2003; Kinlay et al, 2004).
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In contrast, the effect of statins on macrophage-like THP-1 cells in vitro 
shown in this thesis suggests that the drugs not only act to reduce 
inflammatory markers at the level of the liver but may also have a local effect 
on reducing IL-6 gene expression in macrophages in the atherosclerotic 
lesion. By reducing inflammation in the lesion it may be possible to reduce 
or retard lesion development and thereby reduce recurrent ischaemic events, 
which may explain the MIRACL trial results and provide further evidence for 
the use of statins.
7.2 IL-6 gene expression in primary monocyte-derived macrophages 
from healthy individuals o f known IL-6 promoter haplotype 
A primary monocyte-derived macrophage model of inflammation was 
optimised for the quantitation of IL-6 gene expression under conditions of 
inflammatory challenge. Monocyte-derived macrophages were stimulated 
with three different inflammatory challenges to show if there was a common 
mechanism for the IL-6 promoter haplotype-specific gene activation. The 
results of the chromatin accessibility (CHART-PCR) assays and the gene 
expression experiments showed a stimulus-specific IL-6 response, but only 
stimulation with IL-ip produced a significant haplotype-specific mRNA 
response. The stimulus-specific data were consistent with different pathways 
of receptor-signalling. It is not clear whether the varied response of the 
population studied is due to stimulus-specific transcription factor binding, 
however there is a stimulus-specific difference in active chromatin across the 
proximal IL-6 promoter and this response varied according to the region of 
the proximal IL-6 promoter. This suggests that the regions of the IL-6
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promoter co-operate to contribute to IL-6 gene expression and although the 
response to IFN-y and LPS was not haplotype-specific, there is nonetheless 
an overall contribution of promoter organisation to IL-6 gene expression, 
which could be regulated by IL-6 promoter haplotype. The IL-6 protein 
concentration in cell culture supernatants was not significantly haplotype- 
specific, although cells from the +GG9/11G IL-6 promoter haplotype did 
produce slightly higher levels of IL-6 at baseline and when stimulated. 
Moreover, monocyte-derived macrophages from normal, healthy individuals 
were able to respond to the inflammatory challenges by producing IL-6, 
regardless of IL-6 promoter haplotype, which could explain why there is little 
consensus in the literature on the role of IL-6 promoter genotypes in disease.
IFN-y and LPS have been shown to upregulate IL-6 mRNA expression within 
60 minutes of stimulation in a calcium independent manner (Marriott et al, 
1998). It has been previously reported that macrophages exhibit a 
differential response to LPS with or without priming with IFN-y (Feng et al, 
2004; Hayes et al, 1995). This synergistic effect was also seen in human 
retinal pigment epithelial cells stimulated with LPS and IFN-y and resulted in 
a ten fold induction of IL-6 production (Nagineni et al, 1994). IFN-y priming 
for LPS response resulted in the upregulation of toll-like receptor 4/MD-2 
complexes and MyD88, activation of interleukin-1 receptor associated kinase, 
NF-kB activation and cytokine production in monocyte-derived macrophages 
(Bosisio et al, 2002). No significant increase in IL-6 mRNA expression was 
observed in the small study presented here, which could be due to the
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duration of priming with IFN-y being 12 or 24 hours compared to 40 hours 
(Bosisio et al, 2002).
A sequential test of association of each of the seven IL-6 promoter 
polymorphisms revealed that only the -373 9A/1 IT  allele was associated with 
a significantly higher IL-6 response to IL-ip stimulation. This is consistent 
with the data from the comparison of the IL-6 proximal promoter haplotype 
(+GG9/11G) when stimulated with IL-ip.
Analysis of the IL-6 promoter using UCSC Genome Browser 
(http://qenome.ucsc.edu/) showed that of the polymorphisms genotyped, only 
the promoter SNP -174 was within a highly conserved region in a comparison 
of 17 species (LCD score 220), although it was previously reported that the 
length of -373 AnTn region was highly conserved (Kelberman et al, 2004). 
The IL-6 -174 G/C SNP has been extensively studied with respect to disease 
association with little consensus on its role. The data in this thesis from 
normal, healthy volunteers did not show a significant role of the -174 SNP on 
its own. Moreover, a significant association in IL-6 mRNA expression was 
observed with the IL-6 -373 9/11 genotype.
A previous report in an ex vivo model showed no difference between the IL-6 
-597 G, -572 G, -174 G haplotype and other IL-6 promoter haplotypes 
stimulated with LPS. On closer inspection of the work however, it was clear 
that the authors were not working from a baseline monocyte-derived 
macrophage model. These results were observed in a whole blood assay of
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IL-6 mRNA expression (Muller-Steinhardt et al, 2007) and this makes the 
result difficult to interpret in the context of the data presented in this thesis, 
although it does suggest that genotyping the -373 AnTn polymorphism in the 
IL-6 promoter may have shown haplotype-specific differences.
An AU rich region has been identified in the 3’ UTR in human IL-6 mRNA 
(Neininger et al, 2002). AU rich elements (AREs) contribute to the localisation 
of mRNA, translation, and degradation, that is, they play a role in IL-6 mRNA 
stability. In mice, LPS induced IL-6 gene expression depends on MAPKAP 
kinase 2, and this was shown to be regulated through ARE translational 
control. Second messengers may increase mRNA stability; for example 
leukotriene B4, a lipid mediator of inflammation, increases the half life of IL-6 
mRNA from one to three hours by a mechanism of increased transcription 
and stability (Rola-Pleszczynski and Stankova, 1992). IL-6 mRNA under 
basal conditions has a half life of 30 minutes and is destabilised by AUF1, a 
nuclear protein and ARE-specific mRNA destabilising factor (Paschoud et al, 
2006). IL-6 mRNA in osteoclasts stimulated with IL-ip has a half life of 90 
to i20 minutes whilst in the presence of the p38 MAP kinase inhibitor 
SB203580 this was reduced to 24 minutes (Patil et al, 2004), suggesting that 
p38 is required for IL-6 activation. In MC3T3-E1 osteoclast cells stably 
transfected with the IL-6 3’UTR, it was demonstrated that the main target of 
p38 MAP kinase activity was the 3' UTR of the IL-6 gene. In human 
fibroblast-like synoviocytes, IL-ip activation of MAP p38 kinase resulted in 
the stabilisation of IL-6 mRNA possibly through activation of AUF1 AU rich 
element binding protein in the 3’ UTR (Miyazawa etal, 1998). These findings
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suggest an additional mechanism of regulation of IL-6 expression in 
inflammatory conditions, where the IL-6 mRNA half life could be extended.
7.3 Mechanisms o f normal IL-6 promoter activation 
The chromatin accessibility assay is a quantitative ‘snapshot’ of chromatin 
remodelling events. Chromatin accessibility is determined by epigenetic 
modification, including histone acétylation, méthylation, phosphorylation and 
ubiquitination (Im et al, 2004). Previous reports suggest that chromatin 
accessibility is cell-type specific. In monocytic cell lines stimulated with IL-ip 
chromatin remodelling events are required for inducible immediate-early 
response genes. This is a dynamic process, involving the recruitment of key 
transcriptional activators, including GK2, and leads to cytokine gene 
regulation (Liang et al, 2006). Using CHART-PCR chromatin remodelling 
was obvious in the IL-2 proximal promoter from 1.5 hours to 16 hours in 
murine EL-4 and primary CD4+ T cells stimulated with PMA (Rao et al, 
2001). However, no chromatin remodelling was seen in the IL-2 promoter in 
CD4+CD25+Treg cells stimulated with PMA (Su et al, 2004), consistent with 
these cells not producing IL-2.
This cell type specific difference was observed between monocytic and 
macrophage-like THP-1 cells stimulated with IL-ip, IFN-y or LPS in the three 
regions of the IL-6 promoter. There was greater chromatin remodelling in the 
IL-6 promoter in the macrophage-like cells than in the monocytic cells, which 
was consistent with higher IL-6 gene expression in the former.
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In primary monocyte-derived macrophages from healthy individuals of known 
IL-6 promoter haplotype, chromatin remodelling was shown to be time-, 
stimulus and IL-6 promoter region-dependent. It was shown that chromatin 
remodelling in the IL-6 promoter is a dynamic process, occurring rapidly 
within 30 minutes of IL-ip stimulation of monocyte-derived macrophages. 
There were IL-6 promoter haplotype specific differences in chromatin 
accessibility, although not statistically significant, and this does suggest a 
possible mechanism of haplotype-specific IL-6 expression. This is the first 
report of detailed differential chromatin remodelling events across the IL-6 
proximal promoter and provides evidence for the role of chromatin 
remodelling in the regulation of IL-6 gene activation in a monocyte-derived 
macrophage model of inflammation.
Five DNase I hypersensitive sites have previously been identified in the IL-6 
promoter at position -1400, -600, -150, +200, +400. These were identified 
by DNase I footprinting using Southern blotting in breast cancer cell lines 
(Armenante et al, 1999). This method is not quantitative. The hypersensitive 
sites at -600 and -150 are within the IL-6 proximal promoter region 1 and 
region 3 respectively. In the present study, however, a DNase I 
hypersensitive region was identified from -340 to -470. The difference could 
be due to the numbering of the basepairs. In the present study, the labelling 
nomenclature is from the start of transcription (-1, indicated in Appendix I) a 
difference of 64 bases from the translational start. It is more likely that the 
early methods of identifying DNase I hypersensitivity could not accurately 
pinpoint the region. However, the results presented here, that the IL-6
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proximal promoter has a region or regions of DNase I hypersensitivity, are 
consistent with the earlier data, although in a different cell type. DNase I 
hypersensitive sites are associated with promoter regulatory function and 
structure (Elgin, 1988). Nucleosomes are excluded from DNase I 
hypersensitive sites, which allows regulatory regions of genes to be 
accessible to transcription activation complexes. In this thesis, the finding of 
a DNase I hypersensitive site in region 2 of the IL-6 proximal promoter was 
made in primary cells derived from four individuals and not from a cell line. In 
spite of the biological differences between individuals, there was still a strong 
DNase I hypersensitive response in region 2 of the IL-6 promoter. Region 2 
includes the variable AnTn polymorphic region at position -373 which was 
shown to be associated with a higher IL-6 mRNA response to 1L-1(3 
stimulation and suggests that this could be a key regulatory element in the IL- 
6 promoter.
The CHART-PCR approach was also used to quantitate DNase I 
hypersensitive regions in the mouse p-globin locus control region in foetal 
liver cells. The authors identified weak, strong and intermediate 
hypersensitive sites. These intermediate sites were flanking strong 
hypersensitive regions but were constrained by nucleosomes (McArthur et al, 
2001). Nucleosomes have been shown in yeast cells to exhibit a DNA 
sequence preference, based on the ability of the sequence to loop into 
nucleosomes (loshikhes et al, 2006; Segal et al, 2006). This genome 
positioning of nucleosomes was shown to be functional and predictable , that 
is related to regions of gene regulation (Segal et al, 2006). There are low
149
numbers of nucleosomes around transcription start sites. Promoters with a 
TATA box within a nucleosome positioning sequence appear to be regulated 
by chromatin remodelling (loshikhes etal, 2006).
The IL-10 promoter was shown to have a DNase I hypersensitive site in 
macrophages but not T cells, that is macrophage-specific chromatin 
packaging (Saraiva etal, 2005). Chromatin accessibility was associated with 
a transient phosphorylation of histone protein H3 (Ser10) at specific sites in 
the IL-10 promoter and transcription factor binding (Zhang et al, 2006), 
necessary for gene expression. It would be useful to determine if this 
macrophage-specific chromatin response was seen in the IL-6 promoter and 
would have implications for the IL-6/IL-10 balance in regulating the 
inflammatory response in macrophages.
A region of thirteen AT repeats in yeast chromatin in the 3’ region of the 
FBP1 gene was shown by T7 Endonuclease I digestion to have a cruciform 
structure. This region was part of a nuclease sensitive site flanked by 
nucleosomes (Del Olmo et al, 1993; Del Olmo and Perez-Ortin, 1993). The 
cruciform extrusion depended on the supercoiled state of DNA. Deleting the 
ATi3 region abolished the hypersensitive site but did not alter the 
nucleosome position (Aranda etal, 1997).
Although cruciform folding was not predicted by MFOLD or Kinefold 
(Xayaphoummine et al, 2005) (http://kinefold.curie.fr/cqi-bin/form.pl). a 
version of web software for shorter sequences of DNA which predicted the
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same folding profiles as MFOLD), digestion of the IL-6 promoter chromatin 
from monocyte-derived macrophages suggested the presence of cruciform 
secondary structure within the IL-6 proximal promoter. This has not been 
shown previously but is consistent with the DNase I hypersensitivity in region 
2 of the IL-6 promoter.
Previous reports on cruciform extrusion have shown that negative 
supercoiling of the DNA double strand is required for cruciform or Holliday 
junction formation (Mikheikin et al, 2006). This was studied by atomic force 
microscopy in a supercoiled plasmid (Shlyakhtenko et al, 2000). Ruv A binds 
four-way junctions and the protein-DNA complexes were visualised on AFM. 
The images presented here show potential cruciform structures within 
supercoiled DNA based on the expected view. The numbers of cruciforms 
were not quantitated as there were insufficient fields in this pilot study, but 
the supercoiled structure was clearly visible.
Taken together these results suggest that a DNase I hypersensitive site in 
the IL-6 promoter region 2 is associated with cruciform structure and that 
region 2 may be flanked by constraining nucleosomes. The regions on either 
side of region 2 show intermediate DNase I sensitivity and are affected by the 
cruciform structure in region 2 (summarised in Figure 7.1). There is no 
evidence in the present study of haplotype-specific cruciform formation, 
however, it is a small study and is thus not conclusive.
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Figure 7.1. A model of IL-6 promoter structure and function
Panel A shows the linear arrangement of the proximal IL-6 promoter 
including the transcription factor binding sites and locations of the single 
nucleotide polymorphisms and the variable AT tract in region 2. A DNase I 
hypersensitive site, associated with open chromatin, was demonstrated in 
region 2 of the IL-6 proximal promoter (panel B). It is suggested that 
nucleosomes on either side of the AT tract in region 2 constrain the DNA 
double helix, resulting in cruciform extrusion (panel C), which could affect 
transcription factor binding and gene expression.
Another mechanism to consider is the effect of the variable AnTn 
polymorphism on the curvature of the DNA helix. DNA curvature, the twisting
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and writhing of DNA, affects transcription. Curvature of the DNA structure is 
a conserved feature of promoter organisation (Marilley and Pasero, 1996). A 
polyA-poly-T region in DNA was preferentially associated with DNA bending 
(Hagerman, 1986) and stacking of the A-T bases, as seen in the folding 
predictions of the IL-6 promoter haplotypes, is linked to helix formation 
(Dickerson, 1998). There are usually 10.4bp to a DNA helix (Wang, 1979), 
however it is possible, though not proved here, that the variable length AnTn 
(8A/12T, 9A/1 IT, 10A/10T, 10A/11T) region in the IL-6 promoter at position - 
373, is subject to variable curvature and could therefore affect the relative 
positioning of transcription factors on either side of the AT tract, and IL-6 
gene expression.
This project studied the normal genetic variation and normal activation of IL-6 
in healthy volunteers of known IL-6 promoter haplotype. IL-6 mRNA 
expression was induced in a haplotype-specific manner in response to IL-ip 
stimulation. Regulatory elements were identified in the IL-6 promoter. 
Haplotype-specific dysregulation of IL-6 and/or an imbalance with anti­
inflammatory cytokines such as IL-10 could account for the varied disease 
associations reported.
7.4 Future work
The data presented here point to region specific chromatin remodelling, 
DNase I hypersensitivity and cruciform structure within the IL-6 promoter. 
The CHART-PCR regions could be further refined to provide a more detailed 
picture of the dynamic process of chromatin remodelling. Chromatin
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immunoprécipitation could be used to determine which transcription factors 
or complexes bind in each region of the promoter under different conditions 
of stimulation. This approach was used to study regulation of the IL-10 
promoter in T cells and T helper cells (Kang and Im, 2005). A novel 
approach using anti-cruciform antibodies (Frappier et al, 1989) and QPCR 
could be used to immunoprecipitate and identify cruciform regions in the IL-6 
promoter.
Transcription factor binding databases were used to determine if there was a 
consensus on transcription factors to look for with chromatin 
immunoprécipitation. MATInspector (http://www.qenomatix.de) and 
TFSEARCH (http://www.cbrc.ip/htbin/nph-tfsearch) both identified a putative 
FINF-3 forkhead homologue 2 (FlfH-2) binding site in the region of the IL-6 - 
373 AnTn region. This was not genotype-specific. PROMOTERSCAN 
(http://zeon.well.ox.ac.uk) and TFBIND (http://tfbind.hqc.ip/) identified the 
known transcription factors binding sites and additional potential sites with a 
lower weighting, such as HNF-4, with no predicted haplotype-specific 
difference. It could therefore be a complex of frans-activation factors which 
contributes to haplotype-specific IL-6 mRNA expression. For example, co- 
operativity between the NF-kB and NF-IL6 transcription factors in the 
regulation of the IL-6 promoter in human prostate cancer cells (Xiao et al, 
2004a) and NF-kB co-operation between the c-Jun and AP-1 sites in human 
multiple myeloma cells (Xiao et al, 2004b).
Further ex vivo studies could be undertaken to study the effects of inhibition 
of the receptor-signalling pathway components to identify which components
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are activated and necessary for IL-6 transcription. Microarray studies would 
identify up-and down-regulated components of the process in this model, 
instead of the single output measured in this study.
In addition, this study only considers the role of chromatin remodelling in the 
proximal promoter, although the individuals have been genotyped for the 
distal promoter polymorphisms. It may provide additional information on the 
mechanisms of IL-6 promoter activation to consider the effect of all seven 
promoter polymorphisms on chromatin accessibility, although the present 
analysis of IL-6 mRNA expression confirmed that the -373 AnTn 
polymorphism was the only influence on IL-ip stimulated mRNA expression. 
It would also inform the study of IL-6 regulation to determine other sites of 
DNase I hypersensitivity across the IL-6 gene.
The AFM pilot study showed that the technique can be used to study DNA 
secondary structure at high resolution. By increasing the concentration of 
plasmid and therefore the number of molecules per field, the cruciform 
structures could be quantitated to determine if there is a haplotype-specific 
difference in IL-6 promoter cruciform. By choosing an appropriate negative 
control, that is, native plasmid, it could be shown that the cruciform structure 
occurs specifically within the IL-6 promoter construct.
A similar ex vivo study in primary macrophages from individuals with 
inflammatory conditions such as coronary artery disease or inflammatory
155
bowel disease could reveal dysregulation of the IL-6 promoter and provide a 
meaningful explanation for disease occurrence.
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Appendix I Annotated Interleukin-6 gene and promoter 
Legend
ATG/TAG start/stop codon
ta ta box
Exon 1 81 bp
Exon 2191 bp
Exon 3 114bp
Exon 4 147bp
Exon 5 592bp
Bold CAPS = CDS
Unbold CAPS = EXONS
Polymorphisms
lower case = introns
-2049 cagccaggat caaacagctg ggaagacgag aaaacctttc ccaggctagg -2000
-1999 ataacagagg atttggttga aaatacaggc aattaggtgc tacctctggg -1950
-1949 aaaaggggcc aggagaggaa ggagacactt ttccctgcat gccctgatgt -1900
-1899 cctatttgaa cattttatca tgaacacgaa cttcctattt aaaaaacact -1850
-1849 ttttattgaa aagataaatc tgtgtgttgt attgtgtcac tcagttcaag -1800
-1799 tacttgaaat ttattgaatt gtattttcta aaaaatagat agttgagtaa -1750
-1749 aagcaagctc acattacata gacggatcac agtgcacggc tgcggagctg rs2069824 T/C -1700
-1699 ggagcagtgg cttcgtttca tgcaggaaag agaacttggt tcaggagtgt -1650
-1649 ctacgttgct taagacagga gagcactaaa aatgaaacca tccagccatc -1600
-1599 ctcccccatt rs2069825 [• ttcattttca-/CT] caccaaagaa tcccaccgcg gcagaggacc -1550
-1549 accgtctctg tttagacaat cggtgaagaa tggatgacct cactttcccc -1500
-1499 aacaggcggg tcctgaaatg ttatgcacgars2069827 aacaaaacttG/T gagtaaatgc -1450
-1449 ccaacagagg tcactgtttt atcgatcttg aagagatctc ttcttagcaa -1400
-1399 agcaaagaaa ccgattgtga aggtaacacc atgtttggta aataagtgtt -1350
-1349 ttggtgttgt gcaagggtct ggtttcagcc tgaagccatc tcagagctgt -1300
-1299 ctgggtctct ggagactgga gggacaacct agtctagagc ccatttgcat -1250
-1249 gagaccaagg atcctcctgc aagagacacc atcctgaggg aagagggctt -1200
-1199 ctgaaccagc ttgacccaat aagaaattct tgggtgccga cgcggaagca -1150
-1149 gattcagagc ctagagccgt gcctgcgtcc gtagtttcct tctagcttct -1100
-1099 tttgatttca aatcaagact tacagggaga gggagcgata aacacaaact -1050
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1049 ctgcaagatg ccacaaggtc ctcctttgac atccccaaca aagaggtgag -1000
-999 tagtattctc cccctttctg ccctgaacca agtgggcttc agtaatttca -950
-949 gggctccagg agacctgggg cccatgcagg tgccccagtg aaacagtggt -900
-899 gaagagactc agtggcaatg gggagagcac tggcagcaca aggcaaacct -850
-849 ctggcacaga gagcaaagtc ctcactggga ggattcccaa ggggtcactt -800
-799 gggagagggc agggcagcag ccaacctcct ctaagtgggc tgaagcaggt -750
-749 gaagaaagtg gcagaagcca cgcggtggca aaaaggagtc
rsl800797
acacactcca 
' A/G
-700
-699 cctggagacg ccttgaagta actgcacgaa 
rsl800796 G/C
atttgaggat ggccaggcag -650
-649 ttctacaaca gccgctcaca gggagagcca gaacacagaa gaactcagat -600
-599 gactggtagt attaccttct tcataatccc aggcttgggg ggctgcgatg -550
-549 gagtcagagg aaactcagtt cagaacatct ttggttttta caaatacaaa 
rs7802307 AnTn
-500
— 4 9 9 ttaactggaa cgctaaattc tagcctgtta atctggtcac tgaaaaaaaa -450
-449 tttttttttt ttcaaaaaac atagctttag cttatttttt ttctctttgt -400
-399 aaaacttcgt gcatgacttc agctttactc tttgtcaaga catgccaaag -350
-349 tgctgagtca ctaataaaag aaaaaaagaa agtaaaggaa gagtggttct -300
-299 gcttcttagc gctagcctca atgacgacct 
rsl800795 G/C
aagctgcact tttcccccta -250
-249 gttgtgtctt gcgatgctaa aggacgtcac attgcacaat cttaataagg -200
-199 tttccaatca gccccacccg ctctggcccc acGctcaccc tccaacaaag -150
-149 atttatcaaa tgtgggattt tcccatgagt ctcaatatta
-1
gagtctcaac
EXONl
-100
-99 ccccaataaa tatagqactg gagatgtctg aggctcaTTC TGCCCTCGAG -50
-49 CCCACCGGGA ACGAAAGAGA AGCTCTATCT CCCCTCCAGG AGCCCAGCTA 1
2 TGAACTCCTT CTCCACAAgt aagtgcagga aatccttagc cctggaactg 51
52 ccagcggcgg tcgagccctg tgtgagggag gggtgtgtgg cccagggagg 101
102 gctggcgggc ggccagcagc agaggcaggc tcccagctgt gctgtcagct 151
152 cacccctgcg ctcgctcccc tccggcacag gcgccttcgg tccagttgtg 201
202 aactccttct ccacaagtaa gtgcaggaaa tccttagccc tggaactgcc 251
252 agcggcggtc gagccctgtg t g a g g g a g g g gtgtgtggcc cagggagggc 301
302 tggcgggcgg ccagcagcag aggcaggctc ccagctgtgc tgtcagctca 
EXON2
351
352 cccctgcgct cgctcccctc cggcacagGC GCCTTCGGTC CAGTTGCCTT 401
402 CTCCCTGGGG CTGCTCCTGG TGTTGCCTGC TGCCTTCCCT GCCCCAGTAC 451
158
452 CCCCAGGAGA AGATTCCAAA GATGTAGCCG CCCCACACAG ACAGCCACTC 501
502 ACCTCTTCAG AACGAATTGA CAAACAAATT CGGTACATCC TCGACGGCAT 551
552 CTCAGCCCTG AGAAAGGAGg tgggtaggct tggcgatggg gttgaagggc 601
602 ccggtgcgca tgcgttcccc ttgcccctgc gtgtggccgg gggctgcctg 651
652 cattaggagg tctttgctgg gttctagagc actgtagatt tgaggccaac 701
702 ggggccgact agactgactt ctgtatttat cctttgctgg tgtcaggaag 751
752 ttcctttcct ttctggaaaa tgcagaatgg gtctgaaatc catgcccacc 801
802 tttggcatga gctgagggtt attgcttctc agggcttcct tttccctttc 851
852 caaaaaatta ggtctgtgaa gctccttttt gtcccccggg ctttggaagg 901
902 actagaaaag tgccacctga aaggcatgtt cagcttctca gagcagttgc 951
952 agtacttttt ggttatgtaa actcaatggc taggattcct caaagccatt 1001
1002 ccagctaaga ttcatacctc agagcccacc aaagtggcaa atcataaata 1051
1052 ggttaaagca tctccccact ttcaatgcaa ggtattttgg tcctgtttgg 1101
1102 tagaaagaaa agaacacagg aggggagatt gggagcccac actcgaattc 1151
1152 tggttctgcc aaaccagcct tgtgatcttg ggtaaattcc ctaccacctc 1201
1202 tggactccat cagtaaaatt gggcgtggac taggtgatct catagatcct 1251
1252 tcctgctgga acattctatg gcttgaatta tattctccta attattgtca 
rs2069837 A/G
1301
1302 aaattgctgt tattaagtat ctactgtgtg ccaggcactt taaataaata 1351
1352 ttgtgtctaa tcttcaaaac aaatttgcaa ggaaggtttt tggagataag 1401
1402 gaaactgaga ctcaggatta agtaacacac ctaaagtcac aggtgagctt 1451
1452 ggaactgaac ccaagtgtgc ccccactcca ctggaatttg cttgccagga 1501
1502 tgccaatgag ttgtagcttc atttttctta gagactttcc tggctgtggt 1551
1552 tgaacaatga aaaggccctc tagtggtgtt tgttttaggg acacttaggt 
EX0N3
1601
1602 gataacaatt ctggtattct ttcccagACA TGTAACAAGA GTAACATGTG 1651
1652 TGAAAGCAGC AAAGAGGCAC TGGCAGAAAA CAACCTGAAC CTTCCAAAGA 1701
1702 TGGCTGAAAA AGATGGATGC TTCCAATCTG Gqtaccaact 1751
1752 tgtcgcactc acttttcact attccttagg caaaacttct ccctcttgca 1801
1802 tgcagtgcct gtatacatat agatccaggc agcaacaaaa agtgggtaaa 1851
1852 tgtaaagaat gttatgtaaa tttcatgagg aggccaactt caagcttttt 1901
1902 taaaggcagt ttattcttgg actctgattg tccagttatt taaaatggtg 1951
159
1952 ctgtccaatg tcccaaaaca tgctgcctaa gaggtacttg aagttctcta 2001rs2069840 C/G
2002 gaggagcaga gggaaaagat gtcgaactgt ggcaatttta acttttcaaa 2051
2052 ttgattctat ctcctggcga taaccaattt tcccaccatc tttcctctta 2101
2102 qllAGACTTGC CTGGTGAAAA TCATCACTGG TCTTTTGGAG TTTGAGGTAT 2151
2152 ACCTAGAGTA CCTCCAGAAC AGATTTGAGA GTAGTGAGGA ACAAGCCAGA 2201
2202 GCTGTGCAGA TGAGTACAAA AGTCCTGATC CAGTTCCTGC 2251
2252 gggtgtgtcc tcattccctc aacttggtgt gggggaagac aggctcaaag 2301
2302 acagtgtcct ggacaactca gggatgcaat gccacttcca aaagagaagg 2351
2352 ctacacgtaa acaaaagagt ctgagaaata gtttctgatt gttattgtta 2401
2402 aatctttttt tgtttgtttg gttggttgca aaaaaaaaaa aaagaagttt 2451
2452 gttgctatgg aagggtccta ctcagagcag gcaccccagt taatctcatt 2501
2502 caccccacat ttcacatttg aacatcatcc catagcccag agcatccctc 2551
2552 cactgcaaag gatttattca acatttaaac aatccttttt actttcattt 26013;L“6JEiH EXONS
2 602 tccttcagGC AAAGAATCTA'(|aTGCAATAA CCACCCCTGA CCCAACCACA 2 651
2 652 AATGCCAGCC TGCTGACGAA GCTGCAGGCA CAGAACCAGT GGCTGCAGGA 27 01
27 02 CATGACAACT CATCTCATTC TGCGCAGCTT TAAGGAGTTC CTGCAGTCCA 2751
27 52 GCCTGAGGGC TCTTCGGCAA ATGTAGCATG GGCACCTCAG ATTGTTGTTG 28 01
28 02 TTAATGGGCA TTCCTTCTTC TGGTCAGAAA CCTGTCCACT GGGCACAGAA 2851
28 52 CTTATGTTGT TCTCTATGGA GAACTAAAAG TATGAGCGTT AGGACACTAT 2 901
2 902 TTTAATTATT TTTAATTTAT TAATATTTAA ATATGTGAAG CTGAGTTAAT 2 951
2 952 TTATGTAAGT CATATTTATA TTTTTAAGAA GTACCACTTG AAACATTTTA 3001
3002 TGTATTAGTT TTGAAATAAT AATGGAAAGT GGCTATGCAG TTTGAATATC 3051
3052 CTTTGTTTCA GAGCCAGATC ATTTCTTGGA AAGTGTAGGC TTACCTCAAA 3101
3102 TAAATGGCTA ACTTATACAT ATTTTTAAAG AAATATTTAT ATTGTATTTA 3151
3152 TATAATGTAT AAATGGTTTT TATACCAATA AATGGCATTT TAAAAAATTC 3201
3202 agcaactttg agtgtgtcac gtgaagctta atataaacaa gtttcttgtc 3251
3252 actgccacca ccacgaccaa aaaaagctaa tcaatcacta tatataatac 3301
3302 atatatatac tatatataat aaatatatat actatatata atacatat 3349
16 0
Appendix II Detailed IL-6 promoter haplotype folding predictions
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Appendix IV Poster abstracts and conference proceedings
1. Genetic variation in the Interleukin-6 promoter determines Interleukin- 
6 levels in atherosclerosis. HA Khwaja, LD Beeton and FR Green. 
ISTH, Sydney. August 2005.
2. Interleukin-6 (IL-6) promoter polymorphisms influence the inter­
individual macrophage inflammatory response. L Beeton, H Khwaja, K 
Bodman-Smith, G Ferns and F Green. BAS meeting. Oxford. March 
2006.
3. Interleukin-6 promoter polymorphisms influence the inter-individual 
macrophage inflammatory response. L Beeton, H Khwaja, K Bodman- 
Smith, G Ferns and F Green. IAS. Rome. June 2006.
4. Genetic variation in the Interleukin-6 promoter influences the 
macrophage inflammatory response. L Beeton, H Khwaja, K Bodman- 
Smith, G Ferns and F Green. IVBM, Noordwijkerhout. June 2006.
5. Inhibitory effect of statins on IL-6 mRNA expression in THP-1 cells 
subjected to an inflammatory stimulus. L Beeton, P Tomlin, K 
Bodman-Smith, G Ferns and F Green. IVBM, Noordwijkerhout. June 
2006.
6. Interleukin-6 promoter polymorphisms exert a co-operative influence 
on chromatin remodelling and IL-6 mRNA expression in a monocyte- 
derived macrophage model of inflammation. L Beeton, K Bodman- 
Smith, G Ferns and FR Green. EMVBM, Bristol. September 2007.
Published abstracts from conference proceedings
1. Abstracts of the XIV International Symposium on Atherosclerosis,
Rome, Italy, 18-22 June 2006. Atherosclerosis Vol. 7, no. 3S.
2. Abstracts from the XlVth International Vascular Biology Meeting June
6-10, 2006 Noordwijkerhout, The Netherlands. Vascular
Pharmacology, Volume 45, Issue 3, September 2006, Pages e16-e17.
3. Abstracts from the XlVth International Vascular Biology Meeting June
6-10, 2006 Noordwijkerhout, The Netherlands. Vascular
Pharmacology, Volume 45, Issue 3, September 2006, Page e3.
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